Innovus Pharmaceuticals 10-Q 15 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	14-May-15
Document And Entity Information [Abstract]
Entity Registrant Name	INNOVUS PHARMACEUTICALS, INC.
Entity Central Index Key	1411879
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	INNV
Entity Common Stock, Shares Outstanding		40,810,545
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash	$56,177	$7,479
Accounts receivable	81,148	191,601
Prepaid expenses	84,283	55,024
Deposits	17,391	21,919
Inventory	272,590	265,959
Total Current Assets	511,589	541,982
OTHER ASSETS
Property & equipment, net	68,495	54,511
Goodwill	549,368	429,225
Intangible assets, net	5,756,026	1,055,372
TOTAL ASSETS	6,885,478	2,081,090
CURRENT LIABILITIES
Accounts payable and accrued expenses	383,568	362,160
Deferred revenue	17,586	25,224
Accrued interest payable (current portion)	85,675	52,568
Warrant Liability	194,103
Notes payable, net of debt discount of $164,088 in 2015 and $55,982 in 2014.	305,912	314,018
Debentures - related parties (current portion) , net of debt discount of $82,926	150,108
Total Current Liabilities	1,136,952	753,970
NON-CURRENT LIABILITIES
Accrued compensation	1,042,872	906,928
Notes payable, net of debt discount of $67,726		24,274
Debentures - related parties , net of debt discount of $11,413 and $76,492	355,266	497,586
Contingent consideration	3,229,804	324,379
Total Non-Current Liabilities	4,627,942	1,753,167
TOTAL LIABILITIES	5,764,894	2,507,137
STOCKHOLDERS' EQUITY
Common stock: 150,000,000 shares authorized, at $0.001 par value, 40,775,545 and 27,112,263	40,777	27,113
Additional paid-in capital	13,813,532	10,778,807
Accumulated deficit	12,733,725	11,231,967
Total Stockholders' Equity	1,120,584	-426,047
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$6,885,478	$2,081,090

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, shares authorized	150,000,000
Common stock, par value	$0.00
Common stock, shares issued	40,775,545	27,112,263
Common stock, shares outstanding	40,775,545	27,112,263
Debt discount, notes payable current	$164,088	$55,982
Debt discount, related parties, current	82,926
Notes payable, discount, non current	67,726
Debt discount, related parties, noncurrent	$11,413	$76,492

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Product sales	$196,852	$166,088
REVENUES	196,852	166,088
OPERATING EXPENSES
Cost of product sales	76,420	55,851
Research and development		55,567
General and administrative	1,448,002	1,285,590
Total Operating Expenses	1,524,422	1,397,008
LOSS FROM OPERATIONS	-1,327,570	-1,230,920
Interest expense	-173,882	-208,494
Loss on extinguishment of debt	-32,500
Change in fair value of derivative liability	32,194
NET LOSS	($1,501,758)	($1,439,414)
BASIC LOSS AND DILUTED LOSS PER SHARE	($0.04)	($0.06)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING- BASIC AND DILUTED (in shares)	34,970,677

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	($1,501,758)	($1,439,414)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation	9,053	21,203
Stock-based compensation	630,518	564,226
Common stock and stock units issued for services	264,553	153,754
Loss on extinguishment of debt	32,500
Change in fair value of derivative liability	-32,194
Debt discount	138,899	143,612
Accretion of Debt Discount		41,832
Amortization of intangibles	-92,346	-9,337
Changes in operating assets and liabilities, net of acquisition amounts
Accounts receivable	110,453	5,772
Prepaid Expenses	-19,286	23,155
Deposits	6,961
Inventory	-6,631	-30,315
Accounts payable and accrued expenses	21,408	101,897
Accrued compensation	135,944	158,947
Interest payable	33,107	22,978
Deferred revenue	-7,638	-25,288
Net Cash Used in Operating Activities	-91,765	-248,304
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of equipment	-9,537
Net Cash Used in Investing Activities	-9,537
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes payable, net	100,000	300,000
Proceeds from notes payable - related party	50,000	25,000
Proceeds from convertible debt		4,253
Net Cash Provided by Financing Activities	150,000	329,253
NET CHANGE IN CASH	48,698	80,949
CASH AT BEGINNING OF PERIOD	7,479	33,374
CASH AT END OF PERIOD	56,177	114,323
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Common stock issued for conversion of debt	92,000	742,300
Common Stock issued and potentially issuable for acquisition	4,977,050
Return of Common Stock shares related to license agreement	38,000
Shares issued in conjunction with Debt Amendment	25,659
Beneficial conversion on line of credit	$2,034

NATURE_OF_OPERATIONS_OF_THE_CO

NATURE OF OPERATIONS OF THE COMPANY	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS OF THE COMPANY	Innovus Pharmaceuticals, Inc., together with its subsidiaries (collectively referred to as “Innovus” or the “Company”) is a San Diego, California based commercial-stage pharmaceutical company that delivers safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality, and respiratory diseases.
	The Company has five products that are currently being marketed: (1)Zestra® , a non-medicated, patented consumer care product that has been clinically proven to increase desire, arousal, and satisfaction in women; (2) EjectDelay ® , an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; (3) Sensum+ ® , a non-medicated consumer care cream that increases penile sensitivity (ex-US); (4) Zestra Glide® , a clinically tested high viscosity low osmolality water-based lubricant; and (5) Vesele ®, a proprietary and novel oral dietary supplement to maximize nitric oxide beneficial effects on sexual functions and brain health. Vesele ® contains a patented formulation of L-Arginine and L-Citrulline in combination with the natural absorption enhancer Bioperine®.
	Pipeline Products
	Androferti ®
	On January 28, 2015, we entered into an exclusive distribution agreement with Laboratorios Q Pharma (Spain) to distribute and commercialize Androferti in the U.S. by ourselves and in Canada through our partner. Androferti is a natural supplement that supports overall male reproductive health and sperm quality. Androferti®, has been shown in multiple published clinical trials to statistically increase seminal quality (concentration, motility, morphology and vitality) and  enhances spermatozoa quality (decreases of vacuoles in the sperm nucleus, decreases DNA fragmentation, decreases the dynamics of sperm DNA fragmentation, and improvement on the inventory of mobile sperms.
	Fluticare™ (Fluticasone propionate nasal spray)
	Innovus acquired the worldwide rights to market and sell the Fluticare™ brand (Fluticasone propionate nasal spray) and the related manufacturing agreement from Novalere FP in February of 2015.  Innovus expects that the Abbreviated New Drug Application (“ANDA”) filed in November 2014 by the manufacturer with the U.S. Food and Drug Administration (“ FDA ”) may be approved by the end of 2015 or in the first half of 2016 which will allow the Company to market and sell Fluticare™ over the counter.  An ANDA is an application for a U.S. generic drug approval for an existing licensed medication or approved drug.  Fluticasone Propionate Nasal Spray (“FPNS”) is the #1 most prescribed nasal steroid in the U.S. since 2007, with more than 150 million units sold and has been the #1 prescribed nasal spray to patients in the U.S. for more than five consecutive years.  More than 40 million units of FPNS nasal spray product form have been sold in the U.S. in 2014, and the worldwide market is estimated to be over $1 billion annually.

LIQUIDITY

LIQUIDITY	3 Months Ended
	Mar. 31, 2015
Liquidity and Plan Of Operation [Abstract]
LIQUIDITY	The Company’s operations have been financed primarily through advances from officers, directors and related parties, outside capital, and from revenues generated from the launch of its products and commercial partnerships signed for the sale and distribution of its products domestic and internationally. These funds have provided the Company with the resources to operate its business, to sell and support its products, attract and retain key personnel, and add new products to its portfolio. To date, the Company has experienced net losses and negative cash flows from operations each year since its inception. As of March 31, 2015, the Company had an accumulated deficit of $12,733,725.
	The Company has raised funds through the issuance of debt and the sale of common stock. For the three months ended March 31, 2015 the Company raised $0.15 million in funds, which include $0.1 million from the issuance of a non-convertible debentures to an unrelated third partys in January 2015, and $0.05 million in proceeds from the issuance of an additional non-convertible debt instrument to a related party. The Company has also issued equity instruments in certain circumstances to pay for services from vendors and consultants.
	As of March 31, 2015, the Company had $0.05 million in cash and cash equivalents, $1.1 million in cash available for use under the line of credit convertible debenture with a related party, and $0.1 million in accounts receivable. During the three months ended March 31, 2015, the Company recognized $0.2 million in revenues from sales of its commercially available products.  While the Company had a working capital deficiency of $0.6 million at March 31, 2015, the Company expects that its existing capital resources, revenues from sales of its products, upcoming sales milestone payments from the commercial partners signed for its products, along with the $1.1 million in funds currently available for use under the LOC Convertible Debenture will be sufficient to allow the Company to continue its operations, commence the product development process, and launch selected products through July 1, 2016. (See Note 7)
	While the Company had a working capital deficiency of $0.6 million at March 31, 2015, the Company’s actual needs will depend on numerous factors, including timing of introducing its products to the marketplace, its ability to attract additional ex-US distributors for its products and its ability to in-license in non-partnered territories and/or develop new product candidates.  The Company may also seek to raise capital, debt or equity, from outside sources to pay for further expansion and development of its business, and to meet current obligations. Such capital may not be available to the Company when it needs it on terms acceptable to the Company, if at all.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Basis of Presentation and Principles of Consolidation
	These unaudited condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), and include all assets, liabilities, revenues and expenses of the Company and its wholly owned subsidiaries: FasTrack Pharmaceuticals, Inc., Semprae Laboratories, Inc. (“Semprae”) and Novalere, Inc. (“Novalere”). All material intercompany transactions and balances have been eliminated. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations and the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. Certain information required by U.S. GAAP has been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The results for the period ended March 31, 2015, are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2015 or for any future period.
	Use of Estimates
	The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Such management estimates include equity-based instruments, revenue recognition, sales adjustments, fair value of the derivative liability, and intangible assets. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions.
	Fair Value Measurement
	The Company’s financial instruments are cash, accounts receivable, accounts payable, accrued liabilities, and debt. The recorded values of cash, trade accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The Company believes the recorded values of convertible debentures and convertible debt, net of the discount, approximate the fair value as the interest rate (stated or effective) approximates market rates for similar types of instruments.
	The Company follows a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest priority to measurements involving significant unobservable inputs (Level 3). The three levels of the fair value hierarchy are as follows:
		●	Level 1 measurements are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
		●	Level 2 measurements are inputs other than quoted prices included in Level 1 that are observable either directly or indirectly.
		●	Level 3 measurements are unobservable inputs.
	Concentration of Credit Risk and Major Customers
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash held with financial institutions may exceed the amount of insurance provided by the Federal Deposit Insurance Corporation on such deposits. Accounts receivable consist primarily of amounts receivable from Sothema Laboratories under the Company's licensing agreements (See Note 4) and from sales of Zestra®. The Company also requires a percentage of payment in advance for product orders with its larger partners. The Company performs ongoing credit evaluations of its customers and generally does not require collateral.
	As of March 31, 2015 and December 31, 2014, the Company had $81,148 and $191,601, respectively, in accounts receivable, presented net of estimated returns and allowances.
	The Company had two major customers that accounted for 25% and 17%, respectively, of its total net sales during the three months ended March 31, 2015.  These same customers accounted for 48% and 28%, respectively, of total net accounts receivable as of March 31, 2015.  The Company had three major customers that accounted for 30%, 15% and 12%, respectively, of its total net sales during the three months ended March 31, 2014.
	Concentration of Suppliers
	The Company has manufacturing relationships with a number of vendors or manufacturers for its products including: Sensum+®, EjectDelay®, Vesele®, Androferti® and the Zestra® line of products. Pursuant to these relationships, the Company purchases product through purchase orders with its manufacturers. The Company is in the process of entering into more formal agreements with certain of these manufacturers.
	Inventory
	Inventory, consisting primarily of finished goods, is valued at the lower of cost or market where cost is determined using the first-in, first-out method. The inventory balance at March 31, 2015 is primarily comprised of finished goods for Zestra®, Zestra Glide®, and EjectDelay®. Inventory is shown net of obsolescence and allowance for reducing the inventory cost to market. Obsolescence of inventory is determined based on shelf life or potential product replacement.
	Property and Equipment
	Property and equipment are recorded at historical cost less accumulated depreciation. Depreciation is computed using the straight-line method over their estimated useful lives ranging from three to five years. The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.
	Intangible Assets
	Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives, which range in term from 7 to 15 years. The useful life of the intangible asset is evaluated each reporting period to determine whether events and circumstances warrant a revision to the remaining useful life.
	Intangible assets consist of the following:
			31-Mar-15
			Amount		Accumulated			Net Amount		Useful Lives
					Amortization					(years)
	Patents and trademarks		$	439,608	$	(32,392	)	$	407,215	15-Jul
	Customer contracts			611,119		(77,540	)		533,579	10
	Sensum+® license			234,545		(32,364	)		202,181	10
	Product rights and related Manufacturing Agreement			4,681,000		(67,950	)		4,613,050	10
	Balance Outstanding at March 31, 2015		$	5,966,272	$	(210,246	)	$	5,756,026
			31-Dec-14
					Accumulated					Useful Lives
			Amount		Amortization			Net Amount		(years)
	Patents and trademarks		$	264,321	$	(23,671	)	$	240,650	14-Jul
	Customer contracts			611,119		(62,262	)		548,857	10
	Sensum+™ (formally called CIRCUMserum™) license			272,545		(31,250	)		241,295	10
	Vesele trademark			25,287		(717	)		24,570	8
	Balance Outstanding at December 31, 2014			1,173,272		(117,900	)		1,055,372
	Expected amortization as of March 31, 2015 is approximately $589,000 for each of the next five years, and $2,811,000 thereafter.
	Goodwill
	The Novalere purchase price allocation was based upon an analysis of the fair value of the assets and liabilities acquired from Novalere. The final purchase price may be adjusted up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below (See Note 5).
	The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share.
	The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicates an impairment may have occurred, by comparing its reporting unit's carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The goodwill was recorded as part of the acquisition of Semprae that occurred on December 24, 2013, and the acquisition of Novalere, that occurred on February 5, 2015. There was no impairment of goodwill for the three months ended March 31, 2015 or the year ended December 31, 2014.
	Long-Lived Assets
	The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company evaluates assets for potential impairment by comparing estimated future undiscounted net cash flows to the carrying amount of the asset. If the carrying amount of the assets exceeds the estimated future undiscounted cash flows, impairment is measured based on the difference between the carrying amount of the assets and fair value.
	Financial Instruments
	If a conversion feature of conventional convertible debt is not accounted for separately as a derivative instrument and provides for a rate of conversion that is below market value, this feature is characterized as a Beneficial Conversion Feature (“BCF”). A BCF is recorded by the Company as a debt discount. The Company amortizes the discount to interest expense over the life of the debt using the effective interest rate method. The Company’s February 2014 Convertible Debenture and September 2014 Convertible Debenture each contain a BCF (See Note 7). The Company’s January 2012 and January 2013 Debentures, and LOC Convertible Debenture, which contained an embedded conversion feature, were converted on February 19, 2014 (See Note 8).
	Income Taxes
	Income taxes are provided for using the asset and liability method whereby deferred tax assets and liabilities are recognized using current tax rates on the difference between the financial statement carrying amounts and the respective tax basis of the assets and liabilities. The Company provides a valuation allowance on deferred tax assets when it is more likely than not that such assets will not be realized.
	The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting this standard, the amount recognized in the financial statements is the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement with the relevant tax authority. There were no uncertain tax positions at March 31, 2015.
	Revenue Recognition, Trade Receivables and Deferred Revenue
	The Company generates revenues from product sales and the licensing of the rights to market and commercialize its products.
	The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition.  Revenue is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) price to the buyer is fixed or determinable; and (4) collectability is reasonably assured.
	Product Sales: The Company ships product to its customers pursuant to purchase agreements or orders. Revenue from sales transactions where the buyer has the right to return the product is recognized at the time of sale only if (1) the seller’s price to the buyer is substantially fixed or determinable at the date of sale, (2) the buyer has paid the seller, or the buyer is obligated to pay the seller and the obligation is not contingent on resale of the product, (3) the buyer’s obligation to the seller would not be changed in the event of theft or physical destruction or damage of the product, (4) the buyer acquiring the product for resale has economic substance apart from that provided by the seller, (5) the seller does not have significant obligations for future performance to directly bring about resale of the product by the buyer, and (6) the amount of future returns can be reasonably estimated.
	License Arrangements: Payments received by the Company under license arrangements to market and commercialize its products may include non-refundable upfront fees, license fees, milestone payments for specific achievements designated in the agreements, and royalties on sales of products. The Company considers a variety of factors in determining the appropriate method of accounting under its license arrangements, including whether the various elements can be separated and accounted for individually as separate units of accounting.  For license arrangements in which the Company has completed all of its performance obligations, amounts received at the date of the conclusion of such performance obligations are recognized as revenues.  Subsequent payments of regulatory and sales-based milestones are outside of the Company’s control and will be recognized upon receipt.
	Sales Allowances
	The Company accrues for product returns, volume rebates and promotional discounts in the same period the related sale is recognized.
	The Company’s product returns accrual is primarily based on estimates of future product returns over the period customers have a right of return, which is in turn based in part on estimates of the remaining shelf-life of products when sold to customers. Future product returns are estimated primarily based on historical sales and return rates. The Company estimates its volume rebates and promotional discounts accrual based on its estimates of the level of inventory of its products in the distribution channel that remain subject to these discounts. The estimate of the level of products in the distribution channel is based primarily on data provided by the Company’s customers.
	In all cases, judgment is required in estimating these reserves. Actual claims for rebates and returns and promotional discounts could be materially different from the estimates.
	The Company provides a customer satisfaction warranty on all of its products to customers for a specified amount of time after product delivery. Estimated return costs are based on historical experience and estimated and recorded when the related sales are recognized. Any additional costs are recorded when incurred or when they can reasonably be estimated.
	The estimated reserve for sales returns and allowances, which is included in accounts receivable, was approximately $23,000 at each of March 31, 2015 and December 31, 2014.
	Cost of Product Sales
	Cost of product sales includes the cost of inventory, royalties and inventory reserves. The Company is required to make royalty payments based upon the net sales of three of its marketed products, Zestra®, Sensum+®, and Vesele®.
Research and Development Costs
Research and development (“R&D”) costs, including research performed under contract by third parties, are expensed as incurred. Major components of R&D expenses consist of testing, post marketing clinical trials, material purchases and regulatory affairs.
Stock-based Compensation
The Company accounts for stock-based compensation in accordance with ASC 718, Stock Based Compensation, which requires the recognition of the fair value of stock-based compensation as an expense in the calculation of net income. ASC 718 requires that stock-based compensation expense be based on awards that are ultimately expected to vest. Stock-based compensation for the three months ended March 31, 2015 and 2014 have been reduced for estimated forfeitures. When estimating forfeitures, voluntary termination behaviors, as well as trends of actual option forfeitures, are considered. To the extent actual forfeitures differ from the Company’s current estimates, cumulative adjustments to stock-based compensation expense are recorded.
Except for transactions with employees and directors that are within the scope of ASC 718, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.
Equity Instruments Issued to Non-Employees for Services
Issuances of the Company’s equity for services are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants is determined at the earlier of (a) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (b) the date at which performance is complete, and is based upon the quoted market price of the common stock at the date of issuance (See Note 9).
Comprehensive Loss
Comprehensive loss consists of net loss and other gains and losses affecting stockholders’ equity that, under U.S. GAAP, are excluded from net loss. Comprehensive loss was the same as net loss for the three months ended March 31, 2015 and 2014, as the Company has no other comprehensive income.
Loss per Share
Basic loss per share are computed by dividing net loss by the weighted average number of common shares outstanding during the period presented. Diluted loss per share are computed using the weighted average number of common shares outstanding during the periods plus the effect of dilutive securities outstanding during the periods. For the three months ended March 31, 2015 and 2014, basic earnings per share are the same as diluted earnings per share as a result of the Company’s common stock equivalents being anti-dilutive due to losses of $1,501,758 and $1,439,414, respectively.
The following table shows the anti-dilutive shares excluded from the calculation of basic and diluted loss per common share attributable to the Company as of March 31, 2015 and 2014:
		As of March 31
		2015		2014
Gross number of shares excluded:
Restricted stock units			18,777,382		7,793,523
Stock Options			123,500		31,500
Convertible notes payable			825,000		825,000
Warrants			1,630,973		630,973
Total			21,356,855		9,280,996
The above table does not include the ANDA Consideration Shares related to the Novalere acquisition, as they are considered contingently issuable (See Note 5).
Recent Accounting Pronouncements
In November 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-16, Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share is More Akin to Debt or to Equity. This update clarifies how current guidance should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. In addition, it clarifies that in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (that is, the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weight those terms and features. The effects of initially adopting the new standard should be applied on a modified retrospective basis to existing hybrid financial instruments issued in a form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted. The Company is currently in the process of evaluating whether the adoption of this update will have a material effect on its condensed consolidated financial statements and related disclosures.
In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern .  This update provide guidance in generally accepted accounting principles about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide footnote disclosures.  The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in the applicable standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued).  The amendments in the update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted.  The adoption of the update has been applied to these financial statements and resulted in no impact on the Company’s financial position or results of operations.
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers. This update states a core principle in that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve the core principle, an entity should apply the following steps: 1) identify the contract(s) with the customer; 2) identify the performance obligations in the contract; 3) determine the transaction price; 4) allocate the transaction price to the performance obligation in the contract; and 5) recognize revenue when (or as) the entity satisfies a performance obligation. The amendments in the update are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted.

LICENSE_AGREEMENTS

LICENSE AGREEMENTS	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
LICENSE AGREEMENTS	Tabuk Pharmaceuticals Agreement
	On March 17, 2015, the Company announced that it had entered into an exclusive license agreement with Tabuk Pharmaceuticals, a Saudi Arabian company (“Tabuk”), with large commercial operations in the Middle East and North Africa under which the Company granted to Tabuk an exclusive license to market and sell the Company’s topical treatment for Premature Ejaculation, EjectDelay® , its Sensum+ ® product for increasing penile sensitivity and its Vesele ® product to increase sexual and cognitive health in the Saudi Arabia, Iraq, Sudan, Tunisia, Morocco ( for the Vesele product only),Libya, Algeria, Jordan, Kuwait, Oman, Yemen, and Egypt (collectively the “Territory”).
	Under the agreement, Innovus will receive an upfront payment and is eligible to receive up to approximately $86.5 million U.S. dollars upon and subject to the achievement of sales milestones based on cumulative supplied units of the licensed products in the Territory plus royalties based on Tabuk’s net sales.
	The Company had not recognized any revenue for the three months ended March 31, 2015 pursuant to this agreement.
	Sothema Laboratories Agreement
	On September 23, 2014, the Company entered into an exclusive license agreement with Sothema Laboratories, SARL, a Moroccan publicly traded company (“Sothema”), under which Innovus granted to Sothema an exclusive license to market and sell Innovus’ topical treatment for Female Sexual Interest/Arousal Disorder (“FSI/AD”) (based on the latest Canadian approval of the indication), Zestra® and its high viscosity low osmolality water-based lubricant Zestra Glide® in the North African countries of Egypt, Morocco, Algeria, Tunisia and Libya, the Middle Eastern countries of Iraq, Jordan, Saudi Arabia and the United Arab Emirates and the West African countries of Benin, Burkina Faso, Cape Verde, Gambia, Ghana, Guinea, Guinea-Bissau, Ivory Coast, Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone and Togo (collectively the “Territory”).
	Under the agreement, Innovus received an upfront payment and is eligible to receive up to approximately $171.25 million dollars upon and subject to the achievement of sales milestones based on cumulative supplied units of the licensed products in the Territory, plus a pre-negotiated transfer price per unit.
	Pursuant to the guidance in ASC 605-28, Milestone Method, the milestones are considered substantive. The milestones enhance the value of the products and are the result of the Company’s past efforts. The milestones are reasonable relative to all of the deliverables. The Company will recognize the revenue from the milestone payments when the cumulative supplied units volume is met. During the quarter ended March 31, 2015, the Company recognized $50,000 of revenue for the sales of products, and no revenue was recognized for the sales milestones of the agreement.
	Orimed Pharma Agreement
	On September 18, 2014, the Company entered into an exclusive license agreement with Orimed Pharma (“Orimed”), an affiliate of JAMP Pharma, under which Innovus granted to Orimed an exclusive license to market and sell in Canada, Innovus’ (a) topical treatment for FSI/AD, Zestra®, (b) topical treatment for premature ejaculation, EjectDelay®, (c) product Sensum+® to increase penile sensitivity and (d) high viscosity low osmolality water-based lubricant, Zestra Glide®.
	Under the agreement, Innovus received an upfront payment and is eligible to receive up to approximately $94.5 million Canadian dollars upon and subject to the achievement of sales milestones based on cumulative gross sales in Canada by Orimed plus certain double-digit tiered royalties based on Orimed’s cumulative net sales in Canada.
	Pursuant to the guidance in ASC 605-28, Milestone Method, the milestones and quarterly royalty payments are considered substantive. The milestones enhance the value of the products and are the result of the Company’s past efforts. The milestones are reasonable relative to all of the deliverables. The Company will recognize the revenue from the milestone payments when the cumulative gross sales volume is met.  The Company will recognize the revenue from the royalty payments on a quarterly basis when the cumulative net sales have been met.  During the quarter ended March 31, 2015, the Company did not recognize revenue related to this agreement, and no revenue was recognized for the sales milestones and royalty payments of the agreement.
	Tramorgan Agreement
	On September 18, 2014, the Company entered into an exclusive license and distribution agreement with Tramorgan Limited (“Tramorgan”), pursuant to which Tramorgan will market the Company’s topical consumer care product to increase penile sensitivity, Sensum+® in the United Kingdom (“UK”).
	The agreement has an initial term until December 31, 2016 and can be extended thereafter for a twenty-four month period if Tramorgan has reached certain aggregate sales milestones. Pursuant to the agreement, Innovus is eligible to receive (a) up to $44 million dollars in sales milestone payments based on Tramorgan’s attainment of certain levels of cumulative gross sales amounts plus (b) fifty percent (50%) royalties based on Tramorgan’s net sales after applicable distribution costs in the UK. During the quarter ended March 31, 2015, no revenue was recognized for the sales milestones and royalty payments of the agreement.
	Ovation Pharma Agreements
	On September 9, 2013, the Company entered into a license and distribution agreement with Ovation Pharma SARL (“Ovation”) under which it granted to Ovation an exclusive license to market and sell the Company’s topical treatment for reduced penile sensitivity, Sensum+ ® , in Morocco. Ovation may pay the Company up to approximately $11.3 million upon achievement of certain commercial milestones described in the license and distribution agreement. In addition, Ovation has agreed to certain upfront minimum purchases of Sensum+ ® based upon an agreed upon transfer price and yearly minimum purchases.
	On September 9, 2013 the Company entered into a second license and distribution agreement with Ovation under which it granted to Ovation an exclusive license to market and sell the Company’s topical premature ejaculation treatment, EjectDelay ®, in Morocco. Ovation may pay the Company up to approximately $18.6 million allocated among a fixed upfront license fee and the achievement of regulatory and commercial milestones. In addition, Ovation has agreed to certain upfront minimum purchases of EjectDelay® based upon an agreed upon transfer price and minimum yearly purchases.
	During the quarter ended March 31, 2015, no revenue was recognized for product sales, or the sales milestones and royalty payments related to the agreement.
	CRI License Agreement
	On April 19, 2013, the Company and Centric Research Institute, Inc. (“CRI”) entered into an asset purchase agreement (the “CRI Asset Purchase Agreement”), pursuant to which the Company acquired:
	● all of CRI’s rights in past, present and future Sensum+ ® product formulations and presentations, and
	● an exclusive, perpetual license to commercialize Sensum+ ® products in all territories except for the United States.
	CRI has retained commercialization rights for Sensum+ ® in the United States.
	In consideration for such assets and license, the Company issued to CRI 631,313 shares of the Company’s common stock valued at $250,000 in April 2013. The Company will be required to issue to CRI shares of the Company’s common stock valued at an aggregate of $200,000 for milestones relating to additional clinical data received. The number of shares to be issued was or will be determined based on the average of the closing price for the 10 trading days immediately preceding the issue date. CRI will have certain “piggyback” registration rights with respect to the shares described above, which rights provide that, if the Company registers shares of its common stock under the Securities Act in connection with a public offering, CRI will have the right to include such shares in that registration, subject to certain exceptions. The Company recorded an asset totaling $250,000 related to the CRI Asset Purchase Agreement and will amortize this amount over its estimated useful life of 10 years.
	On January 23, 2015, the Company entered into a settlement agreement with CRI where-by CRI agreed to return 200,000 shares to the Company. The share return was in consideration for the Company completing certain product development and regulatory efforts relating to the sale of the product in foreign territories.  The Company has reduced the value of the original intangible asset related to the CRI License accordingly, based upon the fair market value of the shares returned.
	The CRI Asset Purchase Agreement also requires the Company to pay to CRI up to $7 million in cash milestone payments based on first achievement of certain annual net sales targets plus a royalty based on annual net sales described therein. The obligation for these payments expires on April 19, 2023 or the expiration of the last of CRI’s patent claims covering the product or its use outside the United States, whichever is sooner. No sales milestones have been met under this agreement, and royalties owed to CRI were immaterial and included in net revenues.

BUSINESS_ACQUISITIONS

BUSINESS ACQUISITIONS	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
BUSINESS ACQUISITIONS
	Acquisition of Novalere
	On February 5, 2015 (the "Closing Date”) the Company, Innovus Pharma Acquisition Corporation, a Delaware corporation and a wholly-owned subsidiary of Innovus (“ Merger Subsidiary I ”), Innovus Pharma Acquisition Corporation II, a Delaware corporation and a wholly-owned subsidiary of the Company (“ Merger Subsidiary II ”), Novalere FP, Inc., a Delaware corporation (“ Novalere FP ”), and Novalere Holdings, LLC, a Delaware limited liability company (“ Novalere Holdings ”), as representative of the shareholders of Novalere (the “ Novalere Stockholders ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), pursuant to which Merger Subsidiary I merged into Novalere and then Novalere merged with and into Merger Subsidiary II (the “ Merger ”), with Merger Subsidiary II surviving as a wholly-owned subsidiary of the Company. Pursuant to the articles of merger effectuating the Merger, Merger Subsidiary changed its name to Novalere, Inc.
	With the Merger, Innovus acquired the worldwide rights to market and sell the Fluticare™ brand (Fluticasone propionate nasal spray) and the related manufacturing agreement from Novalere FP.  Innovus anticipates that the ANDA filed in November 2014 by the manufacturer with the U.S. Food and Drug Administration (“ FDA ”) may be approved by the end of 2015 or in the first half of 2016 which will allow the Company to market and sell Fluticare™ over the counter.  An ANDA is an application for a U.S. generic drug approval for an existing licensed medication or approved drug.
	Under the terms of the Merger Agreement, at the Closing Date, the Novalere Stockholders received 50% of the Consideration Shares (the “Closing Consideration Shares”), and the remaining 50% of the Consideration Shares (the “ANDA Consideration Shares”) will be delivered only if an Abbreviated New Drug Application of Fluticasone Propionate Nasal Spray of Novalere Manufacturing Partners   (the “Target Product”) is approved by the Food and Drug Administration (the “ANDA Approval”).  A portion of the Closing Consideration Shares, and if ANDA Approval is obtained prior to the 18 month anniversary of the Closing Date, a portion of the ANDA Consideration Shares, will be held in escrow for a period of 18 months from the Closing Date to be applied towards any indemnification claims by Innovus pursuant to the Merger Agreement.
	In addition, the Novalere Stockholders are entitled to receive, if and when earned, earn-out payments (the “Earn-Out Payments”). For every $5 million in Net Revenue (as defined in the Merger Agreement) realized by sales of Fluticare™ , the Novalere Stockholders will be entitled to receive, on a pro rata basis, $500,000, subject to  cumulative maximum Earn-Out Payments of $2.5 million.
	The closing price of the Company’s common stock on the Closing Date was $0.20 per share. The Company issued 12,947,657 Closing Consideration Shares of its common stock at the Closing Date, the Fair Market Value, (‘FMV”) of the Closing Consideration Shares was $2,071,625 as of the Closing Date.  As mentioned above, 12, 280,796 shares were placed in escrow to cover any potential claims that the Company might have with respect to disclosures made by the Novalere.
	The fair value of the contingent consideration is based on preliminary cash flow projections and other assumptions for the ANDA Consideration shares and the Earn-Out Payments, future changes in the estimate of such contingent consideration will be recognized as a charge to operations expense.
	Issuance of the 12,947,655 ANDA Consideration Shares is subject to milestones, achievement of which is uncertain.  The FMV of the ANDA Consideration Shares was established to account for the uncertainty in the future value of the shares.   The value of the shares as derived using the options pricing model was then weighted based on the probability of achieving the milestones to determine the FMV of the ANDA Consideration Shares and estimated potential share prices at such dates.  Based on the aforementioned calculation the fair market value of the ANDA Consideration shares was determined to be $1,657,300.
	The total fair market value of the considerations issued for the transaction are as follows:
		Shares			FMV
	Closing Consideration Shares		12,947,657		$	2,071,625
	ANDA Consideration Shares		12,947,655			1,657,300
	Total		25,895,312		$	3,728,925
	Based on the assumptions, the fair market value of the Earn Out Payments was determined to be $1,205,000. The preliminary fair values of the future earn out payments was determined by applying the income approach, using several significant unobservable inputs for projected cash flows and a discount rate. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance.
	The total purchase price is summarized as follows:
	Cash Consideration	$	43,124
	Common Stock issued at closing		2,071,625
	ANDA Consideration Shares		1,657,300
	Fair Market Value of Future Earn Out Payments		1,205,000
		$	4,977,049
	The fair values of acquired assets and liabilities are based on preliminary cash flow projections and other assumptions. The preliminary fair values of acquired intangible assets were determined using several significant unobservable inputs for projected cash flows and a discount rate. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance. The transaction has been accounted for as a business combination under the acquisition method of accounting. Accordingly, the tangible assets and identifiable intangible assets acquired and liabilities assumed have been recorded at fair value, with the remaining purchase price recorded as goodwill.
	The fair values of assets acquired and liabilities assumed at the transaction date are summarized below:
	Cash and cash equivalents	$	43,124
	Prepaid expenses and other current assets		25,906
	Total Tangible Assets		69,030
	Product rights and related Manufacturing agreement		4,681,000
	Trademarks		150,000
	Total identifiable Intangible Assets		4,831,000
	Goodwill		120,143
	Total Acquired Assets		5,020,173
	Other current liabilities		(43,124	)
	Total Assumed Liabilities		(43,124	)
	Acquired Assets Net of Assumed Liabilities	$	4,977,049
	The carrying value of current assets and liabilities, and fixed assets in Novalere’s financial statements are considered to be a proxy for the fair value of those assets and liabilities.  Novalere is a pre-commercial organization specializing in selling and marketing nasal steroid products; most of the value in Novalere is applicable to the product rights and related manufacturing agreement. Novalere holds a non-exclusive, worldwide, royalty-free license to market, promote, sell, offer for sale, import and distribute the product. This business relationship is contractual in nature and meets the separability criterion and as a result is considered an identifiable intangible asset recognized separately from goodwill. The value of the business relationship is included in goodwill under US GAAP. Goodwill is calculated as the difference between the fair value of the consideration expected to be transferred and the values assigned to the identifiable tangible assets acquired and liabilities assumed. The acquired goodwill presented in the above table reflects the estimated goodwill from the preliminary purchase price allocation.
	The purchase price allocation is subject to completion of our analysis of the fair value of the assets and liabilities of Novalere as of the date of the acquisition. These adjustments could be material. The final valuation is expected to be completed as soon as practicable but no later than one year from the consummation of the Merger. The establishment of the fair value of the consideration for a Merger, and the allocation to identifiable tangible and intangible assets and liabilities requires the extensive use of accounting estimates and management judgment. The fair values assigned to the assets acquired and liabilities assumed are based on estimates and assumptions from data currently available.
	Supplemental Pro Forma Information for 2015 Acquisition (unaudited)
	The following unaudited supplemental pro forma information for the months ended March 31, 2015, and 2014 assumes the contribution of Novalere had occurred as of January 1, 2015, and 2014, giving effect to purchase accounting adjustments. The pro forma data is for informational purposes only and may not necessarily reflect the actual results of operations had Novalere been operated as part of the Company since January 1, 2015, and 2014.
		Three Months Ended March 31, 2015						Three Months Ended March 31, 2014
		As Reported			Pro Forma (unaudited)			As Reported			Pro Forma (unaudited)
	Revenue	$	196,852		$	196,852		$	166,088		$	166,088
	Net Loss		(1,501,758	)		(1,817,888	)		(1,439,414	)		(2,230,351	)
	Loss per Common Share-basic and diluted	$	(0.04	)	$	(0.04	)	$	(0.06	)	$	(0.06	)
	Shares used in computed net loss per common share		34,970,677			47,918,334			22,540,119			35,487,776
	Purchase of Semprae Laboratories, Inc.
	On December 24, 2013 (the “Semprae Closing Date”), the Company, through Merger Sub obtained 100% of the outstanding shares of Semprae in exchange for the issuance of 3,201,776 shares of the Company’s common stock, which shares represented fifteen percent (15%) of the total issued and outstanding shares of the Company as of the close of business on the Semprae Closing Date, whereupon Merger Sub was renamed Semprae Laboratories, Inc. Also, the Company agreed to pay $343,500 to the New Jersey Economic Development Authority (“NJEDA”) as settlement-in-full for an outstanding loan of approximately $640,000 owed by the former stockholder’s of Semprae, in full satisfaction of the obligation to the NJEDA. In addition, the Company agreed to pay the former shareholders an annual royalty (“Royalty”) equal to five percent (5%) of the net sales from Zestra® and Zestra® Glide and any second generation products derived primarily therefrom (“Semprae Target Product”) up until the time that a generic version of such Semprae Target Product is introduced worldwide by a third party.
	The fair market value of the Company’s common stock issued on the Semprae Closing Date was $0.30 per share, which resulted in a fair market value of $960,530 for the common stock issued to the shareholders of Semprae. The fair value of the shares of common stock issued were determined by quoted market prices that are considered to be Level 1 inputs under the fair value measurements and disclosure guidance.  A portion of the shares issued were held in escrow pending reconciliation of assets received and liabilities assumed at the acquisition date.  At March 31, 2015 approximately $60,000 has been agreed by both parties which is the amount that will be returned to the Company in the form of common stock shares at its then quoted market price.
	The transaction has been accounted for as a business combination under the acquisition method of accounting. Accordingly, the tangible assets and identifiable intangible assets acquired and liabilities assumed have been recorded at fair value, with the remaining purchase price recorded as goodwill. The fair values of current assets and liabilities approximated their book value.  The fair values of acquired assets and liabilities are based on preliminary cash flow projections and other assumptions. The fair values of acquired intangible assets were determined using several significant unobservable inputs for projected cash flows and a discount rate. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance.
	The agreement to pay the annual Royalty resulted in the recognition of a contingent consideration, which is recognized at the inception of the transaction, and subsequent changes to estimate of the amounts of contingent consideration to be paid will be recognized as charges or credits in the statement of operations. The fair value of the contingent consideration is based on preliminary cash flow projections, growth in expected product sales and other assumptions. Based on the assumptions, the fair value of the Royalty was determined to be $308,273 at the date of acquisition. The fair value of the royalty was determined by applying the income approach, using several significant unobservable inputs for projected cash flows and a discount rate of 40% commensurate with the Company’s cost of capital and expectation of the revenue growth for products at their life cycle stage. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance. During 2014, approximately $87,000 was paid under this arrangement and the fair value of the expected royalties to be paid was increased by $103,000.  The fair value of contingent consideration was increased to $324,000 at December 31, 2014, based on the new estimated fair value of the consideration. There was no change to the Contingent Consideration as of March 31, 2015.
	As a result of the acquisition, the Company acquired all of Semprae’s assets and liabilities, including its two women’s products, which were added to the Company’s current portfolio of male sexual dysfunction products and other topical products. The Company maintains a number of international patents and trademarks on the two products acquired from Semprae.
	As a result of the acquisition, the Company acquired all of Semprae’s assets and liabilities, including its two women’s products, which were added to the Company’s current portfolio of male sexual dysfunction products and other topical products. Semprae also maintains a number of international patents and trademarks on its two products.
	The aggregate purchase price consideration was as follows:
	Fair value of common stock issued to Semprae shareholders	$	900,909
	Fair value of contingent royalty payments		308,273
	Net purchase price consideration	$	1,209,182
	The fair values of assets acquired and liabilities assumed at the transaction date are summarized below:
	Cash and cash equivalents	$	3,749
	Accounts receivable		78,445
	Inventory		180,441
	Prepaid expenses		16,362
	Property and equipment		78,973
	Customer contracts		611,119
	Patents		99,894
	Trademarks		160,278
Goodwill		429,225
Accounts Payable		(105,804	)
Debt		(343,500	)
Net Assets Acquired	$	1,209,182

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	CEO Promissory Note
	On January 29, 2014, the Company issued an 8% note in the amount of $25,000, to the Company’s President and Chief Executive Officer. The principal amount and interest are payable on January 22, 2015. This note was amended to extend the maturity date until January 22, 2016. (See Note 8).
	Board Member Debenture
	On May 30, 2014, the Company issued an 8% debenture in the amount of $50,000, to a member of the Company's Board of Directors. The principal amount and interest are payable on May 30, 2015 (See Note 8).
	On August 25, 2014, the Company issued an 8% debenture in the amount of $25,000, to a member of the Company's Board of Directors. The principal amount and interest are payable on August 25, 2015 (See Note 8).
	CFO Debenture
	On June 17, 2014, the Company issued an 8% debenture in the amount of $50,000, to the Company’s Chief Financial Officer. The principal and interest are payable on June 16, 2015 (See Note 8).
	Convertible Debentures
	The Company had several convertible debentures, along with the LOC Convertible Debenture, outstanding to related parties, which were converted to common stock (See Note 8).
	January 2015 Non-Convertible Debenture-CFO
	On January 21, 2015, the Company entered into a securities purchase agreement with the Company’s Chief Financial Officer whereby the Company issued and sold a promissory note in the principal face amount of $55,000 and warrants to purchase up to 250,000 shares of the Company’s common stock for gross proceeds of $50,000.
	The Note is due on July 31, 2015 and accrued a one-time interest charge of 8% on the closing date.  The warrants, are exercisable for five years from the closing date at an exercise price of $0.30 per share of Common Stock.  The warrants contain anti-dilution protection, including ratchet protection upon dilutive issuances. (See Note 8)
	Accrued Compensation-Related Party
	Accrued compensation includes accruals for employee wages and vacation pay. The components of accrued compensation are as follows:
		March 31,		December 31,
		2015		2014
	Wages	$	913,482	$	791,987
	Vacation		129,390		114,941
	Total accrued compensation	$	1,042,872	$	906,928
	Accrued employee wages relate primarily to wages owed to the Company’s Chief Executive Officer and President. Under the terms of his employment agreement, wages are to be accrued but no payment made for so long as payment of such salary would jeopardize the Company’s ability to continue as a going concern.

NOTES_PAYABLE

NOTES PAYABLE	3 Months Ended
	Mar. 31, 2015
Notes Payable [Abstract]
NOTES PAYABLE	The following table summarizes the outstanding unsecured (non-related party) notes payable at March 31, 2015 and December 31, 2014:
		March 31,			December 31,
	Current notes payable:	2015			2014
	January 2015 Non-Convertible Debenture	$	110,000		$	-
	February 2014 Convertible Debenture		330,000			330,000
	August 2014 Debenture		40,000			40,000
	Total current notes payable		480,000			370,000
	Less: Debt discount, net of accretion (current)		(174,088	)		(55,982	)
		$	305,912		$	314,018
	Long-term notes -payable
	September 2014 Convertible Debenture	$	-		$	92,000
	Less: Debt discount, net of accretion (long-term)		-			(67,726	)
		$	-		$	24,274
	February 2014 Convertible Debenture
	On February 13, 2014, the Company entered into a securities purchase agreement with an unrelated third party accredited investor pursuant to which the Company issued a convertible debenture in the aggregate principal amount of $330,000 (issued at an original issue discount of 10%) (the “February 2014 Convertible Debenture”) and a warrant to purchase 250,000 shares of the Company's common stock (“Warrant Agreement”).
	The February 2014 Convertible Debenture bears interest at the rate of 10% per annum and the principal amount and interest are payable on March 13, 2015. The effective interest rate will be calculated considering the original issue discount, the BCF and the Warrant Agreement. The February 2014 Convertible Debenture may be converted in whole or in part at any time prior to March 13, 2015, by the holder at a conversion price of $0.40 per share, subject to adjustment. The Company has the option to redeem the February 2014 Convertible Debenture before its maturity by payment in cash of 125% of the then outstanding principal amount plus accrued interest and other amounts due.
	The February 2014 Convertible Debenture was issued with an original issue discount of $30,000. The original issue discount was included in the balance sheet as a discount to the related debt security and is being accreted as non-cash interest expense over the expected term of the loan.
	The Warrant Agreement provides the holder with the right to acquire up to 250,000 shares of common stock at an exercise price of $0.50 per share, subject to certain adjustments as described in the Warrant Agreement, at any time through the fifth anniversary of its issuance date. The allocated relative fair value of the Warrant Agreement of $96,533 has been included in the balance sheet as a discount to the related debt security and is being accreted as non-cash interest expense over the expected term of the loan.
	On March 12, 2015, the Company entered into an amendment agreement whereby the February 2014 Convertible Debenture was amended. Pursuant to the Agreement, the maturity date of the Debenture was amended from March 13, 2015 to September 13, 2015. In addition, the Debenture was amended so that the Company may prepay the Debenture at its option.
	In connection with the execution of the Agreement, the Company issued 250,000 shares of the Company’s common stock and amended and restated the warrant. The Warrant was originally exercisable until February 13, 2019 for 250,000 shares of Common Stock at an exercise price of $0.50 per share, subject to anti-dilution protection. The Warrant, as amended and restated, has been increased to 500,000 shares, and is exercisable until March 12, 2020 at an exercise price of $0.30 per share of Common Stock. The Warrant, as amended and restated, contains certain anti-dilution protection provisions.
	The February 2014 Convertible Debenture contained a BCF. The intrinsic value of the BCF at the date of issuance was determined by measuring the difference between the accounting conversion price and the intrinsic value of the stock at the commitment date. The Company recorded a debt discount for the intrinsic value of the BCF, which was limited to the proceeds with an offsetting increase to paid-in-capital. The BCF of $179,032 along with the original issue discount of $30,000, has been fully accreted as non-cash interest expense using the effective interest method to the maturity date of March 13, 2015.
	The amendment to the February 2014 Convertible Debenture was considered to be an extinguishment of debt as the terms of the debt instruments immediately before and after the amendment were considered to be substantially different as defined in the accounting guidance. In accordance with debt extinguishment accounting requirements, the new debt instrument was recorded at its fair value as determined on the amendment date. The estimated fair value of the note payable was $260,542, net of related debt discount of $69,458, which has been recorded in the consolidated balance sheet. In addition, the warrants associated with the February 2014 Convertible Debenture have an anti-dilution provision that has been accounted for as a derivative. The Company valued the derivative using a Probability Weighted Black-Scholes Option-Pricing Model and the following inputs, stock price on the day of issuance $0.14, 100% volatility, the term of the warrants (5 years) and the risk-free interest rate 1.51 %. These unobservable inputs represent a Level 3 measurement within the fair value hierarchy. The estimated fair value of the warrants as of March 31, 2015 was $76,299 which has been recorded as a derivative liability in the consolidated balance sheet. The estimated fair value of the warrant liability will be revalued on a quarterly basis and any resulting increases or decreases in the estimated fair value will be recorded as an adjustment to operating earnings. (See Note 9)
	The 2015 Amendment resulted in a net difference of $32,500 has been recorded as an extinguishment loss and is recorded in the other income (expense), net line item of the consolidated statements of operations and other comprehensive loss.
	August 2014 Debenture
	On August 30, 2014, the Company issued an 8% debenture to an unrelated third party investor in the principal amount of $40,000 (the “August 2014 Debenture”). The August 2014 Debenture bears interest at the rate of 8% per annum. The principal amount and interest are payable on August 29, 2015.
	September 2014 Convertible Debenture
	On September 29, 2014, the Company issued a convertible promissory note (the “Note”) to an unrelated third party accredited investor for $50,000. The Note had a principal face amount of $92,000, did not accrue interest and was due on March 28, 2016 (the “Maturity Date”). The Note carries the right to convert any part of the principal amount under the Note into shares of common stock at a conversion price of $0.40 per share (the “Conversion Price”). On the Maturity Date, any outstanding principal due under the Note will be automatically converted into common stock at the Conversion Price. The Note holder is prohibited from converting the Note to the extent that, as a result of such conversion, it beneficially owns more than 9.99%, in the aggregate, of the issued and outstanding shares of common stock calculated immediately after giving effect to the issuance of shares of common stock upon the conversion of the Note.  The September 2014 Convertible Debenture contained a BCF. The intrinsic value of the BCF at the date of issuance was determined by measuring the difference between the accounting conversion price and the intrinsic value of the stock at the commitment date. The Company recorded a debt discount for the intrinsic value of the BCF, which was limited to the proceeds with an offsetting increase to paid-in-capital. The BCF of $37,400 along with the original issue discount of $42,000, has been included in the balance sheet at March 31, 2015 as a discount to the related debt security, and is being accreted as non-cash interest expense over the expected term of the September 2014 Convertible Debenture using the effective interest method.  The implicit interest rate was 41%.
	The September 2014 Convertible Debenture was converted into 230,000 shares common stock according to the terms of the note, by the investor on March 30, 2015. As such, the Company recorded the conversion of the note and the remaining BCF was charged to interest expense.
	January 2015 Non-Convertible Debenture
	On January 21, 2015, the Company entered into a securities purchase agreement with an unrelated third party accredited investor whereby the Company issued and sold a promissory note in the principal face amount of $110,000 and warrants to purchase up to 500,000 shares of the Company’s common stock for gross proceeds of $100,000.
	The Note is due on July 31, 2015 and accrued a one-time interest charge of 8% on the closing date.  The warrants, are exercisable for five years from the closing date at an exercise price of $0.30 per share of Common Stock.  The warrants contain anti-dilution protection, including protection upon dilutive issuances.
	The Warrants issued in connection with the January 2015 notes are measured at fair value and classified as a liability because these warrants contain anti-dilution protection and therefore cannot be considered indexed to the Company’s own stock which is a requirement for the scope exception as outlined under ASC 815. The estimated fair value of the warrants was determined using Probability Weighted Black-Scholes Option-Pricing Model , resulting in a value of $99,999 on the date they were issued. The Debt was recorded using the residual method, at $1, net of a debt discount of $109,999. The discount has been included in the balance sheet at March 31, 2015 as a discount to the related debt security, and is being accreted as non-cash interest expense over the expected term of the January 2015 Non-Convertible Debenture using the effective interest method.  The fair value will be affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability, whichever comes first. The anti-dilution protection for the warrants survives for the life of the warrants which ends in January 2020. (See Note 9)
	Interest Expense
	The Company recognized interest expense on the unsecured (non-related party) notes payable, including amortization of debt discount of $140,737 and $14,492 for the three months ended March 31, 2015 and 2014, respectively.

DEBENTURES_RELATED_PARTIES

DEBENTURES b RELATED PARTIES	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
DEBENTURES b RELATED PARTIES	Certain of the debentures outstanding for the year ended December 31, 2013 were converted in 2014 and were no longer outstanding at March 31, 2015.
		March 31,			December 31,
		2015			2014
	LOC Convertible Debenture	$	424,192		$	424,078
	January 2015 Non-Convertible Debenture-CFO		55,000
	2014 Non-Convertible Notes-Related Party		150,000			150,000
	Total		629,192			574,078
	Less : Debt Discount, net of accretion		(123,818	)		(76,492	)
			505,374			497,586
	Less: Current Portion		(150,108	)		-
	Total	$	355,266		$	497,586
	January 2015 Non-Convertible Debenture-CFO
	On January 21, 2015, the Company entered into a securities purchase agreement with the Company’s Chief Financial Officer whereby the Company issued and sold a promissory note in the principal face amount of $55,000 and warrants to purchase up to 250,000 shares of the Company’s common stock for gross proceeds of $50,000.
	The Note is due on July 31, 2015 and accrued a one-time interest charge of 8% on the closing date.  The warrants, are exercisable for five years from the closing date at an exercise price of $0.30 per share of Common Stock.  The warrants contain anti-dilution protection, including protection upon dilutive issuances.
	The Warrants issued in connection with the January 2015 Non-Convertible Debenture-CFO are measured at fair value and classified as a liability because these warrants contain anti-dilution protection and therefore, cannot be considered indexed to the Company’s own stock which is a requirement for the scope exception as outlined under ASC 815. The estimated fair value of the warrants was determined using Probability Weighted Black-Scholes Option-Pricing Model, resulting in a value of $49,999 on the date they were issued. The Debt was recorded using the residual method, at $1, net of a debt discount of $54,999. The discount has been included in the balance sheet at March 31, 2015 as a discount to the related debt security, and is being accreted as non-cash interest expense over the expected term of the January 2015 Non-Convertible Debenture using the effective interest method.  The fair value will be affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability, whichever comes first. The anti-dilution protection for the warrants survives for the life of the warrants which ends in January 2020. (See Note 9)
	Line of Credit – Convertible Debenture
	In January 2013, the Company entered into a line of credit convertible debenture with its President and Chief Executive Officer (the “LOC Convertible Debenture”). Under the terms of its original issuance: (1) the Company could request to borrow up to a maximum principal amount of $250,000 from time to time; (2) amounts borrowed bore an annual interest rate of 8%; (3) the amounts borrowed plus accrued interest were payable in cash at the earlier of January 14, 2014 or when the Company completes a Financing; and (4) the holder had sole discretion to determine whether or not to make an advance upon the Company’s request.
	During 2013, the LOC Convertible Debenture was further amended to: (1) increase the maximum principal amount borrowable to $1 million; and (2) change the holder’s funding commitment to automatically terminate on the earlier of either (a) when the Company completes a financing with minimum net proceeds of at least $4 million, or (b) July 1, 2016. The securities to be issued upon automatic conversion will be either the Company’s securities that are issued to the investors in the Financing or, if the Financing does not occur by July 1, 2016, shares of the Company’s common stock based on a conversion price of $0.312 per share. The LOC Convertible Debenture continues to bear interest at a rate of 8% per annum. The other material terms of the LOC Convertible Debenture were not changed.
	During the year ended December 31, 2013, the Company borrowed $448,475 pursuant to the LOC Convertible Debenture. The LOC Convertible Debenture contained a BCF of $98,335, which was included in the balance sheet at December 31, 2013 as a discount to the related debt security, and accreted as non-cash interest expense over the expected term of the loan using the effective interest method.
	On February 19, 2014, the Company agreed with the holder of the LOC Convertible Debenture to convert the then outstanding principal and interest owed as of such date into shares of the Company’s common stock at a conversion price of $0.40 per share. The principal and interest amount owed under the LOC Convertible Debenture immediately prior to conversion was $476,165, which was converted into 1,190,411 shares of the Company’s common stock. The debt discount of $89,452 related to the BCF for the converted portion was recorded as interest expense.
	On July 22, 2014, the Company agreed with the holder of the LOC Convertible Debenture to increase the principal amount that may be borrowed from up to $1,000,000 to up to $1,500,000.
	During the three months ended March 31, 2015, the Company borrowed $113, under the LOC Convertible Debenture. The $113 borrowed under the LOC Convertible Debenture along with the accrued interest resulted in a BCF of $2,034. As of March 31, 2015, the Company owed a balance of $424,192 in principal amount under the LOC Convertible Debenture, and there was approximately $1.1 million remaining available to use.
	2014 Non-Convertible Notes-Related Party
	On January 29, 2014, the Company issued an 8% note in the amount of $25,000, to the Company’s President and Chief Executive Officer. The principal amount and interest are payable on January 22, 2015.  The President and Chief Executive Officer has extended the maturity date of the note until December 31, 2015.
	On May 30, 2014, the Company issued an 8% debenture in the amount of $50,000, to a member of the Company's Board of Directors. The principal amount and interest are payable on May 30, 2015.
	On August 25, 2014, the Company issued an 8% debenture in the amount of $25,000, to a member of the Company's Board of Directors. The principal amount and interest are payable on August 25, 2015.
	On June 17, 2014, the Company issued an 8% debenture in the amount of $50,000, to the Company’s Chief Financial Officer. The principal and interest are payable on June 16, 2015.
	Interest Expense
	The Company recognized interest expense on the outstanding debentures to related parties including amortization of the discount, of $31,152 and $493 for the three months ended March 31, 2015 and 2014, respectively.

SHAREHOLDERS_EQUITY

SHAREHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
SHAREHOLDERS' EQUITY	Capital Stock
	The Company is authorized to issue 150.0 million shares, all of which are common stock with a par value of $.001 per share.
	Issuances of Common Stock
	On January 17, 2013, the Company entered into an investor relations agreement with a third party pursuant to which the Company agreed to issue over the term of the agreement an aggregate of 250,000 shares of common stock in exchange for investor relations’ services to be rendered. The Company extended the terms of the investor relations agreement on a monthly basis. For the three months ended March 31, 2015, the Company issued 70,000 shares related to the service rendered.  The Company recognized expense of $11,900, and $44,000 under the investor relations agreements during the three months ended March 31, 2015 and 2014 respectively.
	On March 17, 2015, the Company entered into an agreement with a consultant to provide investor relations services to the Company.   In consideration of such services, the Company issued 28,125 shares during the three months ended March 31, 2015 to the consultant, which were valued at the closing price of the Company’s common stock on the date of issuance. The aggregate value of the shares issued was $3,938 which corresponds to the service period of the consultant’s services.
	On August 27, 2014, the Company agreed to issue 200,000 shares of stock pursuant to a consulting contract with a third party for marketing and public relations services. The Company issued 100,000 shares of stock pursuant to this agreement on September 2, 2014. The remaining 100,000 shares were issued on November 4, 2014.  The Company extended the consulting contract in January of 2015, and agreed to issue an additional 200,000 shares.  The issued shares have been valued at the closing price of the Company’s common stock on the date of issuance and are expensed over the period that the services are rendered.   The Company recognized $12,667 during the three months ended March 31, 2015, related to services provided.
	On March 12, 2015, the Company entered into an amendment agreement with the holder of the February 2014 Convertible Debenture. Pursuant to the Agreement, the maturity date of the Debenture was amended from March 13, 2015 to September 13, 2015.  In connection with the execution of the Agreement, the Company issued 250,000 shares of the Company’s common stock. (See Note 7).
	The Company issued 230,000 shares of common stock upon conversion of the September 2014 Convertible Debenture. The September 2014 Convertible Debenture was converted according to the terms of the note, by the investor on March 30, 2015. (See Note 7).
	On January 23, 2015, the Company entered into a settlement agreement with CRI where-by CRI agreed to return 200,000 shares to the Company. The share return was in consideration for the Company completing certain product development and regulatory efforts relating to the sale of the product in foreign territories. (See Note 4).
	The Company issued an additional 137,500 shares of common stock to other consultants under consulting agreements during the three months ended March 31, 2015.  The shares were issued under the Company’s 2013 Equity Incentive Plan (the “Incentive Plan”) or under the corresponding S-8 Plan, as filed with the Securities Exchange Commission. All issued shares have been valued at the closing price of the Company’s common stock on the date of issuance. The aggregate value of the shares issued was $25,900, and $29,900 for the three months ended March 31, 2015 and 2014, respectively.
	2013 Equity Plan
	The Company has issued share-based stock, stock unit and option awards to employees, non-executive directors and outside consultants under the Incentive Plan, which was approved by the Company’s Board of Directors in February of 2013. The Incentive Plan allows for the issuance of up to 10,000,000 shares of the Company’s common stock to be issued in the form of stock options, stock awards, stock unit awards, stock appreciation rights, performance shares and other share-based awards. The exercise price for all equity awards issued under the Incentive Plan is based on the fair market value of the common stock. Currently, because the Company’s common stock is quoted on the OTCQB, the fair market value of the common stock is equal to the last-sale price reported by the OTCQB as of the date of determination, or if there were no sales on such date, on the last date preceding such date on which a sale was reported. Generally, each vested stock unit entitles the recipient to receive one share of Company common stock which is eligible for settlement at the earliest of their termination, a change in control of the Company or a specified date. Stock units can vest according to a schedule or immediately upon award. Stock options generally vest over a three-year period, first year cliff vesting with quarterly vesting thereafter on the three-year awards, and have a ten-year life. Stock options outstanding are subject to time-based vesting as described above and thus are not performance-based.
	As of March 31, 2015, there were 8,345,239 stock units and 123,500 shares subject to options outstanding, the Company issued 1,071,772 shares as payments for services, and 459,489 shares were available for future grants under the Incentive Plan.
	2014 Equity Plan
	The Company has issued share-based stock, stock unit and option awards to employees, non-executive directors and outside consultants under the Incentive Plan, which was approved by the Company’s Board of Directors in November 2014. The Incentive Plan allows for the issuance of up to 20,000,000 shares of the Company’s common stock to be issued in the form of stock options, stock awards, stock unit awards, stock appreciation rights, performance shares and other share-based awards. The exercise price for all equity awards issued under the Incentive Plan is based on the fair market value of the common stock. Currently, because the Company’s common stock is quoted on the OTCQB, the fair market value of the common stock is equal to the last-sale price reported by the OTCQB as of the date of determination, or if there were no sales on such date, on the last date preceding such date on which a sale was reported. Generally, each vested stock unit entitles the recipient to receive one share of Company common stock which is eligible for settlement at the earliest of their termination, a change in control of the Company or a specified date. Stock units can vest according to a schedule or immediately upon award. Stock options generally vest over a three-year period, first year cliff vesting with quarterly vesting thereafter on the three-year awards, and have a ten-year life. Stock options outstanding are subject to time-based vesting as described above and thus are not performance-based.
	As of March 31, 2015, there were 10,390,000 stock units outstanding, the Company issued 10,390,000 shares to employees and consultants, and 9,630,000 shares were available for future grants under the Incentive Plan.
	Stock-based Compensation
	The stock-based compensation expense for the three months ended March 31, 2015 was $630,518, for the issuance of stock units and stock options. The stock-based compensation expense for the three months ended March 31, 2014 was $564,226. The Company calculates the fair value of the stock units based upon the quoted market value of the common stock at the date of grant. The Company calculates the fair value of each stock option award on the date of grant using the Black-Scholes Option-Pricing Model. For the three months ended March 31, 2015, the following weighted average assumptions were utilized for the stock option granted during the period:
		31-Mar-15
	Expected life (in years)		6
	Expected volatility		222.79	%
	Average risk free interest rate		1.54	%
	Dividend yield		0	%
	The dividend yield of zero is based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends. Expected volatility is based on the historical volatility of the Company’s common shares over the period commensurate with the expected life of the options. Expected life in years is based on the “simplified” method as permitted by ASC Topic 718. The Company believes that all stock options issued under its stock option plans meet the criteria of “plain vanilla” stock options. The Company uses a term of six years for all employee stock options. The risk free interest rate is based on average rates for five and seven year treasury notes as published by the Federal Reserve.
	The following table summarizes the number of options outstanding and the weighted average exercise price:
		Options			Weighted average exercise price		Weighted remaining contractual life (years)		Aggregate intrinsic value
	Outstanding at December 31, 2014		113,000		$	0.37		9.5	$	-
	Granted		10,500			0.14		10		-
	Exercised		-			-		-		-
	Cancelled		-			-		-		-
	Forfeited		-			-		-		-
	Outstanding at March 31, 2015		123,500			0.35		9.3	$	-
	Vested at March 31, 2015		123,500		$	0.35		9.3	$	-
	The aggregate intrinsic value is calculated as the difference between the exercise price of all outstanding options and the quoted price of the Company’s common shares that were in the money at March 31, 2015. At March 31, 2015 and December 31, 2014, the aggregate intrinsic value of all outstanding options was $0.
	The Company granted 10,500 and 92,000 options during the three months ended March 31, 2015 and the year ended December 31, 2014, respectively. The weighted average grant date fair value per share of options granted during the three months ended March 31, 2015 and the year ended December 31, 2014 was $0.14 and $0.31, respectively.
	Stock Units
	The following table summarizes the number of stock units outstanding:
		Restricted Stock Units
	Outstanding at December 31, 2014		8,270,239
	Granted		10,507,143
	Expired		-
	Cancelled		-
	Forfeited		-
	Outstanding at March 31, 2015		18,777,382
	Vested at March 31, 2015		11,403,623
	The vested stock units at March 31, 2015 have not settled and are not showing as issued and outstanding shares of the Company. Settlement of these vested stock units will occur on the earliest of (i) the date of termination of service of the employee or consultant, (ii) change of control of the Company, or (iii) 10 years from date of issuance. Settlement of vested stock units may be made in the form of (i) cash, (ii) shares, or (iii) any combination of both, as determined by the board of directors.
	On February 15, 2013, the Company entered into a stock unit agreement with its President and Chief Executive Officer pursuant to his employment agreement. Under the terms of the agreement, the Company issued 6,000,000 stock units, 2,000,000 of the units vested immediately, while the remaining 4,000,000 vest in eight equal quarterly installments until January 1, 2015, subject to his continued service to the Company as of the vesting date.  As of March 31, 2015, all of the stock units have vested under this agreement. There were 500,000 stock units which vested during the three months ended March 31, 2015 and the Company recognized expense of $210,000 which corresponds to the service period.
	On February 15, 2013, the Company entered into a stock unit agreement with a consultant. Under the terms of the agreement, the Company issued 300,000 stock units, with one thirty-sixth of the units vesting on the 7th day of each month beginning on March 7, 2013, subject to the consultant’s continued service to the Company as of the vesting date. At March 31, 2015, 208,325 shares have vested under this agreement. There were 24,999 stock units which vested during the three months ended March 31, 2015 and the Company recognized expense of $9,333, which corresponds to the service period.
	In connection with the appointment of Ms. Dillen as Executive Vice President, Chief Financial Officer, the Company entered into an employment letter with her on February 6, 2014. Under the terms of the employment letter, Ms. Dillen received 600,000 stock units. 200,000 of the units vested after six months of employment, while the remaining 400,000 vest in eight equal quarterly installments until August 6, 2016, subject to her continued service to the Company as of the vesting date. Ms. Dillen is also eligible to receive a grant of 100,000 stock units when the Company’s shares of common stock are listed on Nasdaq, all subject to Ms. Dillen’s continued employment.  As of March 31, 2015, 300,000 stock units have vested under this agreement. The Company recognized a total expense of $119,933 which corresponds to the service period.
	On February 6, 2014, the Company issued 852,273 stock units to the President and CEO in lieu of cash for the annual bonus.
	In May 2014, the Company issued an additional 75,000 restricted stock units to an employee, which vest according to the Company’s standard vesting plan. As of March 31, 2015, the Company recognized expense of $27,750 which corresponds to the service period.
	During the three months ended March 31, 2015, the Company issued 85,714 stock units to its Board of Directors, related to Board Compensation, and recognized $12,000 of expense related to the stock units.
	On March 31, 2015, the Company issued 10,370,000 restricted stock units to employees and consultants, which vest one-third on the issuance date and then monthly for the next 2 years. As of March 31, 2015, the Company recognized expense of $ 483,933 for the vested units.
	The Company recognized total compensation expense for the three months ended March 31, 2015 of $628,694 for the vested portion of the stock units related to employees.  As of March 31, 2015, compensation expense related to unvested shares not yet recognized in the income statement was $770,459 and is expected to be recognized over an average remaining period of 2 years.
	Warrants
	On December 7, 2011, the Company entered into a promissory note with Dawson James Securities, Inc. (“DJS”) whereby, as compensation for consulting services rendered, the Company agreed to pay DJS a sum of $50,000 at a rate of 8.0% per annum. On January 28, 2013, the Company paid DJS $54,548, which represents the principal and accrued interest due on the note, discharging the note in full. The Company issued 380,973 warrants in connection with the Dawson James notes. The warrants have an exercise price of $0.10 and expire December 6, 2018.
	The Company issued 250,000 warrants in connection with the February 2014 Convertible Debentures. The warrants had an exercise price of $0.50 and expire February 13, 2019 (See Note 4). On March 6, 2015 the Company entered into an agreement with the note holder to extend the February 2014 Convertible Debentures for six months. As consideration for the extension, the Company granted the note holder an additional 250,000 warrants and reduced the exercise price of the warrants from $0.50 to $0.30. (See Note 7).
	The Company issued 750,000 warrants in connection with the January 2015 Non-Convertible Debentures. The warrants, are exercisable for five years from the closing date at an exercise price of $0.30 per share of Common Stock.  The warrants contain anti-dilution protection, including protection upon dilutive issuances. (See Notes 7 and 8).
	At March 31, 2015, there are 1,630,973 fully vested warrants outstanding.
	Warrant Derivative Liability
	The Warrants issued in connection with the January 2015 Non-Convertible Debentures and the February 2014 Convertible Debenture are measured at fair value and classified as a liability because these warrants contain anti-dilution protection and therefore, cannot be considered indexed to the Company’s own stock which is a requirement for the scope exception as outlined under ASC 815. The estimated fair value of the warrants was determined using the Black-Scholes Option-Pricing Model, resulting in a value of $235,736, which was limited to the value of the debt of $150,000 in accordance with the relative fair value method, and $76,299 respectively, on the date they were issued. The fair value will be affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability, whichever comes first. The anti-dilution protection for the warrants survives for the life of the warrants which ends in January 2020 and March 2020. (See Notes 7 and 8).
	The assumptions for the Black-Scholes Option-Pricing Model are represented in the table below for the warrants issued with the January 2015 Non-Convertible Notes and the February 2014 Convertible Debenture , reflected on a per share common stock equivalent basis.
		31-Mar-15
	Expected life (in years)		6
Expected volatility		100	%
Average risk free interest rate		1.54	%
Dividend yield		0	%
The following table presents the changes in fair value of our warrants measured at fair value on a recurring basis for each reporting period-end.
	31-Mar-15
Beginning Balance	$	-
Value of Derivative Liability with January 2015 Non-Convertible Debentures		150,000
Value of Derivative Liability with the February 2014 Convertible Debentures		76,299
Change in Fair Value		11,223
Ending Balance	$	237,522

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	On April 13, 2015, the Company announced that it had entered into an exclusive license and distribution agreement with Oz Biogenics based in Australia (“Oz Biogenics”) under which Innovus Pharma has granted to Oz Biogenics an exclusive ten year distribution right to market and sell in Mynamar and Vietnam, Innovus Pharma’s products including Zestra ® to increase Female Sexual Arousal and Desire and Satisfaction, EjectDelay ® for treating premature ejaculation, Sensum + ® to increase penile sensitivity, Vesele ® for sexual functions and cognitive responses and Zestra Glide ® the high viscosity water based lubricant. The annual minimum orders are approximately eight hundred sixty five thousand dollars over the ten year term of the agreement.
	On April 8, 2015, the Company announced that it had entered into an exclusive license and distribution agreement with BroadMed SAL, a Lebanese company (“BroadMed”) under which Innovus Pharma granted to BroadMed an exclusive license to market and sell in Lebanon Innovus’ product Sensum+ ® to increase penile sensitivity. Under the agreement, Innovus Pharma is eligible to receive up to $11.1 million dollars in upfront and sales milestone payments plus double-digit tiered royalties based on BroadMed’s net sales.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis Of Presentation And Principles Of Consolidation	These unaudited condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), and include all assets, liabilities, revenues and expenses of the Company and its wholly owned subsidiaries: FasTrack Pharmaceuticals, Inc., Semprae Laboratories, Inc. (“Semprae”) and Novalere, Inc. (“Novalere”). All material intercompany transactions and balances have been eliminated. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations and the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. Certain information required by U.S. GAAP has been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The results for the period ended March 31, 2015, are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2015 or for any future period.
Use of Estimates	The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Such management estimates include equity-based instruments, revenue recognition, sales adjustments, fair value of the derivative liability, and intangible assets. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions.
Fair Value Measurement	The Company’s financial instruments are cash, accounts receivable, accounts payable, accrued liabilities, and debt. The recorded values of cash, trade accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The Company believes the recorded values of convertible debentures and convertible debt, net of the discount, approximate the fair value as the interest rate (stated or effective) approximates market rates for similar types of instruments.
	The Company follows a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest priority to measurements involving significant unobservable inputs (Level 3). The three levels of the fair value hierarchy are as follows:
	● Level 1 measurements are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.   ● Level 2 measurements are inputs other than quoted prices included in Level 1 that are observable either directly or indirectly.   ● Level 3 measurements are unobservable inputs.
Cash and Cash Equivalents	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash held with financial institutions may exceed the amount of insurance provided by the Federal Deposit Insurance Corporation on such deposits. Accounts receivable consist primarily of amounts receivable from Sothema Laboratories under the Company's licensing agreements (See Note 4) and from sales of Zestra®. The Company also requires a percentage of payment in advance for product orders with its larger partners. The Company performs ongoing credit evaluations of its customers and generally does not require collateral.
	As of March 31, 2015 and December 31, 2014, the Company had $81,148 and $191,601, respectively, in accounts receivable, presented net of estimated returns and allowances.
	The Company had two major customers that accounted for 25% and 17%, respectively, of its total net sales during the three months ended March 31, 2015.  These same customers accounted for 23% and 16%, respectively, of total net accounts receivable as of December 31, 2014.  The Company had three major customers that accounted for 30%, 15% and 12%, respectively, of its total net sales during the three months ended March 31, 2014.
Concentration of Credit Risk and Major Customers	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash held with financial institutions may exceed the amount of insurance provided by the Federal Deposit Insurance Corporation on such deposits. Accounts receivable consist primarily of amounts receivable from Sothema Laboratories under the Company's licensing agreements (See Note 4) and from sales of Zestra®. The Company also requires a percentage of payment in advance for product orders with its larger partners. The Company performs ongoing credit evaluations of its customers and generally does not require collateral.
	As of March 31, 2015 and December 31, 2014, the Company had $81,148 and $191,601, respectively, in accounts receivable, presented net of estimated returns and allowances.
	The Company had two major customers that accounted for 25% and 17%, respectively, of its total net sales during the three months ended March 31, 2015.  These same customers accounted for 48% and 28%, respectively, of total net accounts receivable as of March 31, 2015.  The Company had three major customers that accounted for 30%, 15% and 12%, respectively, of its total net sales during the three months ended March 31, 2014.
Concentration of Suppliers	Inventory, consisting primarily of finished goods, is valued at the lower of cost or market where cost is determined using the first-in, first-out method. The inventory balance at March 31, 2015 is primarily comprised of finished goods for Zestra®, Zestra Glide®, and EjectDelay®. Inventory is shown net of obsolescence and allowance for reducing the inventory cost to market. Obsolescence of inventory is determined based on shelf life or potential product replacement.
Property, Plant and Equipment	Property and equipment are recorded at historical cost less accumulated depreciation. Depreciation is computed using the straight-line method over their estimated useful lives ranging from three to five years. The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.
Intangible Assets	Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives, which range in term from 7 to 15 years. The useful life of the intangible asset is evaluated each reporting period to determine whether events and circumstances warrant a revision to the remaining useful life.
	Intangible assets consist of the following:
		31-Mar-15
		Amount		Accumulated			Net Amount		Useful Lives
				Amortization					(years)
	Patents and trademarks	$	439,608	$	(32,392	)	$	407,215	15-Jul
	Customer contracts		611,119		(77,540	)		533,579	10
	Sensum+® license		234,545		(32,364	)		202,181	10
	Product rights and related Manufacturing Agreement		4,681,000		(67,950	)		4,613,050	10
	Balance Outstanding at March 31, 2015	$	5,966,272	$	(210,246	)	$	5,756,026
		31-Dec-14
				Accumulated					Useful Lives
		Amount		Amortization			Net Amount		(years)
	Patents and trademarks	$	264,321	$	(23,671	)	$	240,650	14-Jul
	Customer contracts		611,119		(62,262	)		548,857	10
	Sensum+™ (formally called CIRCUMserum™) license		272,545		(31,250	)		241,295	10
	Vesele trademark		25,287		(717	)		24,570	8
	Balance Outstanding at December 31, 2014		1,173,272		(117,900	)		1,055,372
	Expected amortization as of March 31, 2015 is approximately $589,000 for each of the next five years, and $2,811,000 thereafter.
Goodwil	The Novalere purchase price allocation was based upon an analysis of the fair value of the assets and liabilities acquired from Novalere. The final purchase price may be adjusted up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below (See Note 5).
	The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share.
	The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicates an impairment may have occurred, by comparing its reporting unit's carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The goodwill was recorded as part of the acquisition of Semprae that occurred on December 24, 2013, and the acquisition of Novalere, that occurred on February 5, 2015. There was no impairment of goodwill for the three months ended March 31, 2015 or the year ended December 31, 2014.
Long-Lived Assets	The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company evaluates assets for potential impairment by comparing estimated future undiscounted net cash flows to the carrying amount of the asset. If the carrying amount of the assets exceeds the estimated future undiscounted cash flows, impairment is measured based on the difference between the carrying amount of the assets and fair value.
Financial Instruments	If a conversion feature of conventional convertible debt is not accounted for separately as a derivative instrument and provides for a rate of conversion that is below market value, this feature is characterized as a Beneficial Conversion Feature (“BCF”). A BCF is recorded by the Company as a debt discount. The Company amortizes the discount to interest expense over the life of the debt using the effective interest rate method. The Company’s February 2014 Convertible Debenture and September 2014 Convertible Debenture each contain a BCF (See Note 7). The Company’s January 2012 and January 2013 Debentures, and LOC Convertible Debenture, which contained an embedded conversion feature, were converted on February 19, 2014 (See Note 8).
Income Taxes	Income taxes are provided for using the asset and liability method whereby deferred tax assets and liabilities are recognized using current tax rates on the difference between the financial statement carrying amounts and the respective tax basis of the assets and liabilities. The Company provides a valuation allowance on deferred tax assets when it is more likely than not that such assets will not be realized.
	The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting this standard, the amount recognized in the financial statements is the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement with the relevant tax authority. There were no uncertain tax positions at March 31, 2015.
Revenue Recognition, Trade Receivables and Deferred Revenue
	The Company generates revenues from product sales and the licensing of the rights to market and commercialize its products.
	The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition.  Revenue is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) price to the buyer is fixed or determinable; and (4) collectability is reasonably assured.
	Product Sales: The Company ships product to its customers pursuant to purchase agreements or orders. Revenue from sales transactions where the buyer has the right to return the product is recognized at the time of sale only if (1) the seller’s price to the buyer is substantially fixed or determinable at the date of sale, (2) the buyer has paid the seller, or the buyer is obligated to pay the seller and the obligation is not contingent on resale of the product, (3) the buyer’s obligation to the seller would not be changed in the event of theft or physical destruction or damage of the product, (4) the buyer acquiring the product for resale has economic substance apart from that provided by the seller, (5) the seller does not have significant obligations for future performance to directly bring about resale of the product by the buyer, and (6) the amount of future returns can be reasonably estimated.
	License Arrangements: Payments received by the Company under license arrangements to market and commercialize its products may include non-refundable upfront fees, license fees, milestone payments for specific achievements designated in the agreements, and royalties on sales of products. The Company considers a variety of factors in determining the appropriate method of accounting under its license arrangements, including whether the various elements can be separated and accounted for individually as separate units of accounting.  For license arrangements in which the Company has completed all of its performance obligations, amounts received at the date of the conclusion of such performance obligations are recognized as revenues.  Subsequent payments of regulatory and sales-based milestones are outside of the Company’s control and will be recognized upon receipt.
Sales Allowances	The Company accrues for product returns, volume rebates and promotional discounts in the same period the related sale is recognized.
	The Company’s product returns accrual is primarily based on estimates of future product returns over the period customers have a right of return, which is in turn based in part on estimates of the remaining shelf-life of products when sold to customers. Future product returns are estimated primarily based on historical sales and return rates. The Company estimates its volume rebates and promotional discounts accrual based on its estimates of the level of inventory of its products in the distribution channel that remain subject to these discounts. The estimate of the level of products in the distribution channel is based primarily on data provided by the Company’s customers.
	In all cases, judgment is required in estimating these reserves. Actual claims for rebates and returns and promotional discounts could be materially different from the estimates.
	The Company provides a customer satisfaction warranty on all of its products to customers for a specified amount of time after product delivery. Estimated return costs are based on historical experience and estimated and recorded when the related sales are recognized. Any additional costs are recorded when incurred or when they can reasonably be estimated.
	The estimated reserve for sales returns and allowances, which is included in accounts receivable, was approximately $23,000 at each of March 31, 2015 and December 31, 2014.
Cost of Goods Sold	Cost of product sales includes the cost of inventory, royalties and inventory reserves. The Company is required to make royalty payments based upon the net sales of three of its marketed products, Zestra®, Sensum+®, and Vesele®.
Research and Development Costs	Research and development (“R&D”) costs, including research performed under contract by third parties, are expensed as incurred. Major components of R&D expenses consist of testing, post marketing clinical trials, material purchases and regulatory affairs.
Stock-based Compensation	The Company accounts for stock-based compensation in accordance with ASC 718, Stock Based Compensation, which requires the recognition of the fair value of stock-based compensation as an expense in the calculation of net income. ASC 718 requires that stock-based compensation expense be based on awards that are ultimately expected to vest. Stock-based compensation for the three months ended March 31, 2015 and 2014 have been reduced for estimated forfeitures. When estimating forfeitures, voluntary termination behaviors, as well as trends of actual option forfeitures, are considered. To the extent actual forfeitures differ from the Company’s current estimates, cumulative adjustments to stock-based compensation expense are recorded.
	Except for transactions with employees and directors that are within the scope of ASC 718, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.
Equity Instruments Issued to Non-Employees for Services	Issuances of the Company’s equity for services are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants is determined at the earlier of (a) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (b) the date at which performance is complete, and is based upon the quoted market price of the common stock at the date of issuance (See Note 9).
Comprehensive Loss	Comprehensive loss consists of net loss and other gains and losses affecting stockholders’ equity that, under U.S. GAAP, are excluded from net loss. Comprehensive loss was the same as net loss for the three months ended March 31, 2015 and 2014, as the Company has no other comprehensive income.
Loss Per Share	Basic loss per share are computed by dividing net loss by the weighted average number of common shares outstanding during the period presented. Diluted loss per share are computed using the weighted average number of common shares outstanding during the periods plus the effect of dilutive securities outstanding during the periods. For the three months ended March 31, 2015 and 2014, basic earnings per share are the same as diluted earnings per share as a result of the Company’s common stock equivalents being anti-dilutive due to losses of $1,501,758 and $1,439,414, respectively.
	The following table shows the anti-dilutive shares excluded from the calculation of basic and diluted loss per common share attributable to the Company as of March 31, 2015 and 2014:
		As of March 31
		2015		2014
	Gross number of shares excluded:
	Restricted stock units		18,777,382		7,793,523
	Stock Options		123,500		31,500
	Convertible notes payable		825,000		825,000
	Warrants		1,630,973		630,973
	Total		21,356,855		9,280,996
	The above table does not include the ANDA Consideration Shares related to the Novalere acquisition, as they are considered contingently issuable (See Note 5).
New Accounting Pronouncements	In November 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-16, Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share is More Akin to Debt or to Equity. This update clarifies how current guidance should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. In addition, it clarifies that in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (that is, the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weight those terms and features. The effects of initially adopting the new standard should be applied on a modified retrospective basis to existing hybrid financial instruments issued in a form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted. The Company is currently in the process of evaluating whether the adoption of this update will have a material effect on its condensed consolidated financial statements and related disclosures.
	In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern .  This update provide guidance in generally accepted accounting principles about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide footnote disclosures.  The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in the applicable standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued).  The amendments in the update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted.  The adoption of the update has been applied to these financial statements and resulted in no impact on the Company’s financial position or results of operations.
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers. This update states a core principle in that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve the core principle, an entity should apply the following steps: 1) identify the contract(s) with the customer; 2) identify the performance obligations in the contract; 3) determine the transaction price; 4) allocate the transaction price to the performance obligation in the contract; and 5) recognize revenue when (or as) the entity satisfies a performance obligation. The amendments in the update are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Intangible Assets and Goodwill		31-Mar-15
		Amount		Accumulated			Net Amount		Useful Lives
				Amortization					(years)
	Patents and trademarks	$	439,608	$	(32,392	)	$	407,215	15-Jul
	Customer contracts		611,119		(77,540	)		533,579	10
	Sensum+® license		234,545		(32,364	)		202,181	10
	Product rights and related Manufacturing Agreement		4,681,000		(67,950	)		4,613,050	10
	Balance Outstanding at March 31, 2015	$	5,966,272	$	(210,246	)	$	5,756,026
		31-Dec-14
		Amount		Accumulated Amortization			Net Amount		Useful Lives (years)
	Patents and trademarks	$	264,321	$	(23,671	)	$	240,650	14-Jul
	Customer contracts		611,119		(62,262	)		548,857	10
	Sensum+™ (formally called CIRCUMserum™) license		272,545		(31,250	)		241,295	10
	Vesele trademark		25,287		(717	)		24,570	8
	Balance Outstanding at December 31, 2014	$	1,173,272	$	(117,900	)	$	1,055,372
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share		As of March 31
		2015		2014
	Gross number of shares excluded:
	Restricted stock units		18,777,382		7,793,523
	Stock Options		123,500		31,500
	Convertible notes payable		825,000		825,000
	Warrants		1,630,973		630,973
	Total		21,356,855		9,280,996

BUSINESS_ACQUISITIONS_Tables

BUSINESS ACQUISITIONS (Tables)	3 Months Ended
	Mar. 31, 2015
Schedule of ProForma information		Three Months Ended March 31, 2015						Three Months Ended March 31, 2014
		As Reported			Pro Forma (unaudited)			As Reported			Pro Forma (unaudited)
	Revenue	$	196,852		$	196,852		$	166,088		$	196,088
	Net Loss		(1,501,758	)		(1,817,888	)		(1,439,414	)		(2,230,351	)
	Loss per Common Share-basic and diluted	$	(0.04	)	$	(0.04	)	$	(0.06	)	$	(0.06	)
	Shares used in computed net loss per common share		34,970,677			47,918,334			22,540,119			35,487,776
Semprae Laboratories Inc [Member]
Schedule of Business Acquisitions and purchase price
	The total fair market value of the considerations issued for the transaction are as follows:
		Shares			FMV
	Closing Consideration Shares		12,947,657		$	2,071,625
	ANDA Consideration Shares		12,947,655			1,657,300
	Total		25,895,312		$	3,728,925
	Based on the assumptions, the fair market value of the Earn Out Payments was determined to be $1,205,000. The preliminary fair values of the future earn out payments was determined by applying the income approach, using several significant unobservable inputs for projected cash flows and a discount rate. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance.
	The total purchase price is summarized as follows:
	Cash Consideration	$	43,124
	Common Stock issued at closing		2,071,625
	ANDA Consideration Shares		1,657,300
	Fair Market Value of Future Earn Out Payments		1,205,000
		$	4,977,049
Schedule of Assets Acquired and Liabilities Assumed	Cash and cash equivalents	$	43,124
	Prepaid expenses and other current assets		25,906
	Total Tangible Assets		69,030
	Product rights and related Manufacturing agreement		4,681,000
	Trademarks		150,000
	Total identifiable Intangible Assets		4,831,000
	Goodwill		120,143
	Total Acquired Assets		5,020,173
	Other current liabilities		(43,124	)
	Total Assumed Liabilities		(43,124	)
	Acquired Assets Net of Assumed Liabilities	$	4,977,049
NovalereMember
Schedule of Business Acquisitions and purchase price	The aggregate purchase price consideration was as follows:
	Fair value of common stock issued to Semprae shareholders	$	900,909
	Fair value of contingent royalty payments		308,273
	Net purchase price consideration	$	1,209,182
Schedule of Assets Acquired and Liabilities Assumed	Cash and cash equivalents	$	3,749
	Accounts receivable		78,445
	Inventory		180,441
	Prepaid expenses		16,362
	Property and equipment		78,973
	Customer contracts		611,119
	Patents		99,894
	Trademarks		160,278
	Goodwill		429,225
	Accounts Payable		(105,804	)
	Debt		(343,500	)
	Net Assets Acquired	$	1,209,182

RELATED_PARTY_TRANSACTIONS_Tab

RELATED PARTY TRANSACTIONS (Tables)	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Schedule of Accrued Compensation		March 31,		December 31,
		2015		2014
	Wages	$	913,482	$	791,987
	Vacation		129,390		114,941
	Total accrued compensation	$	1,042,872	$	906,928

NOTES_PAYABLE_Tables

NOTES PAYABLE (Tables)	3 Months Ended
	Mar. 31, 2015
Notes Payable [Abstract]
Schedule of Notes Payable
		March 31,			December 31,
	Current notes payable:	2015			2014
	January 2015 Non-Convertible Debenture	$	110,000		$	-
	February 2014 Convertible Debenture		330,000			330,000
	August 2014 Debenture		40,000			40,000
	Total current notes payable		480,000			370,000
	Less: Debt discount, net of accretion (current)		(174,088	)		(55,982	)
		$	305,912		$	314,018
	Long-term notes -payable
	September 2014 Convertible Debenture	$	-		$	92,000
	Less: Debt discount, net of accretion (long-term)		-			(67,726	)
		$	-		$	24,274

DEBENTURES_RELATED_PARTIES_Tab

DEBENTURES b RELATED PARTIES (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Convertible Debt		March 31,			December 31,
		2015			2014
	LOC Convertible Debenture	$	424,192		$	424,078
	January 2015 Non-Convertible Debenture-CFO		55,000
	2014 Non-Convertible Notes-Related Party		150,000			150,000
	Total		629,192			574,078
	Less : Debt Discount, net of accretion		(123,818	)		(76,492	)
			505,374			497,586
	Less: Current Portion		(150,108	)		-
	Total	$	355,266		$	497,586

SHAREHOLDERS_EQUITY_Tables

SHAREHOLDERS' EQUITY (Tables)	3 Months Ended
	Mar. 31, 2015
Schedule of Share-based Compensation, Stock Options		Options			Weighted average exercise price		Weighted remaining contractual life (years)		Aggregate intrinsic value
	Outstanding at December 31, 2014		113,000		$	0.37		9.5	$	-
	Granted		10,500			0.14		10		-
	Exercised		-			-		-		-
	Cancelled		-			-		-		-
	Forfeited		-			-		-		-
	Outstanding at March 31, 2015		123,500			0.35		9.3	$	-
	Vested at March 31, 2015		123,500		$	0.35		9.3	$	-
Schedule of Share-based Compensation, Restricted Stock Units
		Restricted Stock Units
	Outstanding at December 31, 2014		8,270,239
	Granted		10,507,143
	Expired		-
	Cancelled		-
	Forfeited		-
	Outstanding at March 31, 2015		18,777,382
	Vested at March 31, 2015		11,403,623
Schedule of Warrant activity		31-Mar-15
	Beginning Balance	$	-
	Value of Derivative Liability with January 2015 Non-Convertible Debentures		150,000
	Value of Derivative Liability with the February 2014 Convertible Debentures		76,299
	Change in Fair Value		11,223
	Ending Balance	$	237,522
Warrant [Member]
Schedule Of Assumptions Used		31-Mar-15
	Expected life (in years)		6
	Expected volatility		100	%
	Average risk free interest rate		1.54	%
	Dividend yield		0	%
Employee Stock Option [Member]
Schedule Of Assumptions Used		31-Mar-15
	Expected life (in years)		6
	Expected volatility		222.79	%
	Average risk free interest rate		1.54	%
	Dividend yield		0	%

LIQUIDITY_Details_Textual

LIQUIDITY (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Retained Earnings (Accumulated Deficit), Total	($12,766,225)
Line of Credit Facility, Remaining Borrowing Capacity	1,000,000
Line of Credit Facility, Cash Available for use	1,100,000
Cash and Cash Equivalents, at Carrying Value	56,177
Working capital	-600,000
Revenues	196,852	166,088
Accounts receivable	100,000
Jan 2014 Convertible Debenture [Member]
Proceeds from issuance of debt and borrowings	100,000
LOC Convertible Debenture [Member]
Proceeds from issuance of debt and borrowings	200,000
Chief Executive Officer [Member]
Line of Credit Facility, initial limit	1,000,000
Line Of Credit Facility, Maximum Borrowing Capacity	$1,500,000

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Intangible assets, Amount	5,966,272	1,173,272
Intangible assets, Accumulated Amortization	-210,246	-117,900
Intangible assets, Net Amount	5,756,026	1,055,372
Patents and Trademarks [Member]
Intangible assets, Amount	439,608	64,321
Intangible assets, Accumulated Amortization	-32,392	-23,671
Intangible assets, Net Amount	407,215	240,650
Patents and Trademarks [Member] | Minimum [Member]
Intangible assets, Useful Lives (years)	7 years	7 years
Patents and Trademarks [Member] | Maximum [Member]
Intangible assets, Useful Lives (years)	15 years	14 years
Customer Contracts [Member]
Intangible assets, Amount	611,119	611,119
Intangible assets, Accumulated Amortization	-77,540	-62,262
Intangible assets, Net Amount	533,579	548,857
Intangible assets, Useful Lives (years)	10 years	10 years
Licensing Agreements [Member]
Intangible assets, Amount	234,545	272,545
Intangible assets, Accumulated Amortization	-32,364	-31,250
Intangible assets, Net Amount	202,181	241,295
Intangible assets, Useful Lives (years)	10 years	10 years
Manufacturing Agreements [Member]
Intangible assets, Amount	4,681,000
Intangible assets, Accumulated Amortization	-67,950
Intangible assets, Net Amount	4,613,050
Intangible assets, Useful Lives (years)	10 years
Vesele [Member]
Intangible assets, Amount		25,287
Intangible assets, Accumulated Amortization		-717
Intangible assets, Net Amount		24,570
Intangible assets, Useful Lives (years)		8 years

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	21,356,855	9,280,996
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,630,973	630,973
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	825,000	825,000
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,235,000	31,500
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	18,777,382	7,793,523

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)	3 Months Ended		12 Months Ended	1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	8-May-15
Accounts Receivable, Net, Current, Total	$81,148		$191,601
Finite-Lived Intangible Assets, Amortization Expense, Year One to Five	589,000
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	2,811,000
Revenue Recognition, Sales Returns, Reserve for Sales Returns	23,000		23,000
NET LOSS	-1,534,258	-1,439,414
Sothema [Member]
License fee received	50,000			36,500
Wal-Mart [Member]
License fee received				$11,000
Customer 1 [Member]
Concentration Risk, Percentage	25.00%	30.00%
Risk, receivables	48.00%
Customer 2 [Member]
Concentration Risk, Percentage	17.00%	15.00%
Risk, receivables	28.00%
Customer 3 [Member]
Concentration Risk, Percentage		12.00%

LICENSE_AGREEMENTS_Details_Tex

LICENSE AGREEMENTS (Details Textual) (USD $)	3 Months Ended		1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	8-May-15	Dec. 31, 2014	Mar. 17, 2015	Nov. 14, 2014	Sep. 09, 2013
Stock To Be Issued During Period For Services Value	$285,142
Finite-Lived Intangible Assets, Accumulated Amortization	210,246			117,900
Amortization of Intangible Assets	92,346	9,337
Tabuk [Member]
Maximum Milestone Payments					86,500,000
Sothema [Member]
Maximum Milestone Payments						17,125,000
License fee received	50,000		36,500
Orimed [Member]
Maximum Milestone Payments						94,500,000
License fee received	0
Tramorgan [Member]
Maximum Milestone Payments	44,000,000
License fee received	0
Ovation Agmt 1 [Member]
Maximum Milestone Payments							11,300,000
CRI Asset Purchase Agreement [Member]
Maximum Milestone Payments	7,000,000
Stock To Be Issued During Period For Services Value	250,000
Stock To Be Issued During Period For Services Shares	631,313
CRI Asset Purchase Agreement [Member] | Criteria One [Member]
Stock To Be Issued During Period For Services Value	$200,000

BUSINESS_ACQUISITIONS_Details

BUSINESS ACQUISITIONS (Details) (NovalereMember, USD $)	Mar. 31, 2015
Business Acquisition [Line Items]
Common Stock	$25,895,312
Fair Market Value of Contingent Consideration - Royalty	3,728,925
ClosingShares [Member]
Business Acquisition [Line Items]
Common Stock	12,947,657
Fair Market Value of Contingent Consideration - Royalty	2,071,625
ANDAShares [Member]
Business Acquisition [Line Items]
Common Stock	12,947,655
Fair Market Value of Contingent Consideration - Royalty	$1,657,300

BUSINESS_ACQUISITIONS_Details_

BUSINESS ACQUISITIONS (Details 1) (NovalereMember, USD $)	Mar. 31, 2015
Business Acquisition [Line Items]
Cash consideration	$43,124
Fair Market Value of Contingent Consideration - Royalty	3,728,925
Fair Market Value of Future Earn Out Payments	1,205,000
Net Purchase Price Consideration	4,977,049
ClosingShares [Member]
Business Acquisition [Line Items]
Fair Market Value of Contingent Consideration - Royalty	2,071,625
ANDAShares [Member]
Business Acquisition [Line Items]
Fair Market Value of Contingent Consideration - Royalty	$1,657,300

BUSINESS_ACQUISITIONS_Details_1

BUSINESS ACQUISITIONS (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015
Business Acquisition [Line Items]
Closing price stock	$0.00
NovalereMember
Business Acquisition [Line Items]
Cash consideration	$43,124
Common Stock	25,895,312
Fair Market Value of Contingent Consideration - Royalty	3,728,925
Fair Market Value of Future Earn Out Payments	1,205,000
Escrow shares	12,280,796
Net Purchase Price Consideration	4,977,049
Earn out payment maximum	2,500,000
Closing price stock	$0.20
NovalereMember | ClosingShares [Member]
Business Acquisition [Line Items]
Common Stock	12,947,657
Fair Market Value of Contingent Consideration - Royalty	2,071,625
NovalereMember | ANDAShares [Member]
Business Acquisition [Line Items]
Common Stock	12,947,655
Fair Market Value of Contingent Consideration - Royalty	$1,657,300

BUSINESS_ACQUISITIONS_Details_2

BUSINESS ACQUISITIONS (Details 2) (Semprae Laboratories Inc [Member], USD $)	Mar. 31, 2015
Semprae Laboratories Inc [Member]
Business Acquisition [Line Items]
Common Stock	$960,530
Fair Market Value of Contingent Consideration - Royalty	308,273
Net Purchase Price Consideration	$1,268,803

BUSINESS_ACQUISITIONS_Details_3

BUSINESS ACQUISITIONS (Details 3) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill	$549,368	$429,225
Semprae Laboratories Inc [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	3,749
Accounts receivable	78,445
Inventory	180,441
Prepaid expenses	16,362
Property and equipment	78,973
Customer contracts	611,119
Patents	99,894
Trademarks	160,278
Goodwill	421,372
Accounts Payable	-38,330
Debt	-343,500
Net Assets Acquired	1,268,803
Common Stock	960,530
Fair Market Value of Contingent Consideration - Royalty	308,273
Net Purchase Price Consideration	$1,268,803

BUSINESS_ACQUISITIONS_Details_4

BUSINESS ACQUISITIONS (Details Textual 1) (Semprae Laboratories Inc [Member], USD $)	1 Months Ended
	Dec. 24, 2013	Mar. 31, 2015
Semprae Laboratories Inc [Member]
Business Acquisition [Line Items]
Percentage Of Ownership Interests	100.00%
Outstanding Loan Amount Paid	$343,500
Loans Outstanding	640,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	3,201,776
Percentage Of Issued And Outstanding Shares	15.00%
Net Sales Annual Royalty Percentage	5.00%
Business Acquisition Equity Interest Issued Or Issuable Fair Value Per Share	$0.30
Business Acquisition Equity Interest Issued Or Issuable, Fair Value		960,530
Percentage Of Discount Rate	40.00%
Fair value of royalty		$308,273

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Notes Payable [Abstract]
Wages	$913,482	$791,987
Vacation	129,390	114,941
Total accrued compensation	$1,042,872	$906,928

RELATED_PARTY_TRANSACTIONS_Det1

RELATED PARTY TRANSACTIONS (Details Textual) (USD $)	3 Months Ended		1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jan. 21, 2015
Notes Issued To Related Parties	$50,000	$25,000
Chief Executive Officer [Member]
Debt Issuance Date	29-Jan-14
Notes Issued To Related Parties	25,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Maturity Date	22-Jan-15
Director [Member]
Debt Issuance Date	30-May-14
Notes Issued To Related Parties	50,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Maturity Date	30-May-15
Director 2 [Member]
Debt Issuance Date	25-Aug-14
Notes Issued To Related Parties	25,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Maturity Date	25-Aug-15
Chief Financial Officer [Member]
Debt Issuance Date	17-Jun-14		21-Jan-15
Notes Issued To Related Parties	50,000		55,000
Warrants issued			250,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%		8.00%
Debt Instrument, Maturity Date	16-Jun-15
Proceeds from non-convertible debenture			$50,000

NOTES_PAYABLE_Details

NOTES PAYABLE (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Promissory Notes	$480,000	$370,000
Less: Debt discount, net of accretion	-164,088	-55,982
Notes Payable, Current, Total	305,912	314,018
Long-term notes payable		24,274
February 2014 Debenture [Member]
Promissory Notes	330,000
August 2014 Debenture [Member]
Promissory Notes	40,000
Jan 2015 Debenture [Member]
Promissory Notes	110,000	350,000
September 2014 Debenture [Member]
Promissory Notes
Less: Debt discount, net of accretion		67,726
Long-term notes payable		92,000
February 2014 Debunture [Member]
Promissory Notes
January 2013 Debenture [Member]
Promissory Notes		$20,000

NOTES_PAYABLE_Details_1

NOTES PAYABLE (Details 1)	3 Months Ended
	Mar. 31, 2015
Notes Payable [Abstract]
Expected life (in years)	6 years
Expected volatility	100.00%
Average risk free interest rate	1.54%
Dividend yield	0.00%

NOTES_PAYABLE_Details_Textuals

NOTES PAYABLE (Details Textuals) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Promissory Notes	$480,000		$370,000
Proceeds from note issuance	100,000	300,000
Loss on extinguishment of debt	-32,500
Notes Payable, Current, Total	305,912		314,018
Interest expense, including Amortization of debt discount	173,882	208,494
Convertible Notes Payable [Member]
Interest expense, including Amortization of debt discount	140,737	14,492
February 2014 Debenture [Member]
Promissory Notes	330,000
Debt Instrument, Interest Rate, Effective Percentage	10.00%
Less: Debt discount, net of accretion	30,000
Warrants To Purchase For Issuance Of Common Stock	250,000
Debt Instrument, Convertible, Conversion Price	$0.40
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed	125.00%
Amortization of Debt Discount (Premium)	30,000
Warrant exercise price	$0.50
Fair value, warrants	96,533
Beneficial conversion	179,032
February 2014 Debenture [Member] | Warrant Mod [Member]
Loss on extinguishment of debt	32,500
Notes Payable, Current, Total	260,542
Warrants To Purchase For Issuance Of Common Stock	500,000
Debt Instrument, Convertible, Conversion Price	$0.30
Common stock issued	250,000
Fair value, warrants	76,299
August 2014 Debenture [Member]
Promissory Notes	40,000
Debt Instrument, Interest Rate, Effective Percentage	8.00%
September 2014 Debenture [Member]
Promissory Notes
Proceeds from note issuance	50,000
Debt Instrument, Interest Rate, Effective Percentage	41.00%
Stock issued	230,000
Less: Debt discount, net of accretion	42,000
Debt Instrument, Convertible, Conversion Price	$0.40
Beneficial conversion	37,400
Jan NonConv 2015 Debenture [Member]
Promissory Notes	110,000
Proceeds from note issuance	100,000
Debt Instrument, Interest Rate, Effective Percentage	8.00%
Warrants To Purchase For Issuance Of Common Stock	500,000
Amortization of Debt Discount (Premium)	109,999
Fair value, warrants	$99,999

DEBENTURES_RELATED_PARTIES_Det

DEBENTURES - RELATED PARTIES (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Convertible Debentures	$629,192	$574,078
Debt Discount, net of accretion	-123,818	-76,492
Convertible Debentures- related parties (See Note64)	505,374	497,586
Less: Current portion	-150,108
Total	355,266	497,586
Debt [Member]
Convertible Debentures	205,000	150,000
LOC Convertible Debenture [Member]
Convertible Debentures	$424,192	$424,078

DEBENTURES_RELATED_PARTIES_Det1

DEBENTURES - RELATED PARTIES (Details Textual) (USD $)	3 Months Ended		1 Months Ended		12 Months Ended	1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jan. 21, 2015	Aug. 11, 2014	Dec. 31, 2014	Feb. 19, 2014
Cash proceeds from debt issued	$50,000	$25,000
Convertible Debt	505,374				497,586
Other Notes Payable, Current	480,000				370,000
Interest Expense, Debt	31,152	493
Line of Credit Facility, Remaining Borrowing Capacity	1,000,000
Chief Executive Officer [Member]
Cash proceeds from debt issued	25,000
Debt Instrument, Interest Rate, Effective Percentage Rate Range, Minimum	8.00%
Debt Instrument, Maturity Date	22-Jan-15
Board of Directors 1 [Member]
Cash proceeds from debt issued	50,000
Debt Instrument, Interest Rate, Effective Percentage Rate Range, Minimum	8.00%
Debt Instrument, Maturity Date	30-May-15
Board of Directors 2 [Member]
Cash proceeds from debt issued	25,000
Debt Instrument, Interest Rate, Effective Percentage Rate Range, Minimum	8.00%
Debt Instrument, Maturity Date	25-Aug-15
Chief Financial Officer [Member]
Cash proceeds from debt issued	50,000		55,000
Debt Instrument, Interest Rate, Effective Percentage Rate Range, Minimum	8.00%
Debt Instrument, Maturity Date	16-Jun-15
Line of Credit [Member]
Debt Conversion Convertible Instrument Share Price					$0.31
Debt Instrument, Interest Rate, Effective Percentage Rate Range, Minimum					8.00%
Line of credit increase to new limit				1,500,000
Line of credit facility borrowed					448,475
Beneficial conversion feature					98,335
January 2013 Debenture [Member]
Debt Conversion, Converted Instrument, Amount						76,122
Cash proceeds from debt issued					70,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)						190,304
Interest and Debt Expense, Total						16,965
Beneficial conversion feature					18,651
January Fifteen 2013 Line Of Credit [Member]
Debt Conversion Convertible Instrument Share Price	$0.40
Debt Conversion, Converted Instrument, Amount	476,165
Debt Conversion, Converted Instrument, Shares Issued (in shares)	1,190,411
Debt Instrument, Interest Rate, Effective Percentage Rate Range, Minimum	8.00%
Interest and Debt Expense, Total	89,452
Line of Credit Facility, Maximum Borrowing Capacity	1,000,000
Line of credit facility borrowed	113
Beneficial conversion feature	2,034
Line of Credit, balance owed	424,192
Line of Credit Facility, Remaining Borrowing Capacity	$1,100,000

SHAREHOLDERS_EQUITY_Details

SHAREHOLDERS' EQUITY (Details)	3 Months Ended
	Mar. 31, 2015
Expected life (in years)	6 years
Expected volatility	100.00%
Average risk free interest rate	1.54%
Dividend yield	0.00%
Employee Stock Option [Member]
Expected life (in years)	6 years
Expected volatility	222.79%
Average risk free interest rate	1.54%
Dividend yield	0.00%

SHAREHOLDERS_EQUITY_Details_1

SHAREHOLDERS' EQUITY (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2015	Sep. 30, 2014
Aggregate intrinsic value, Outstanding	$0
Employee Stock Option [Member]
Stock Options, Outstanding Beginning Balance	113,000
Options, Granted	10,500	75,000
Options, Exercised
Options, Cancelled
Options, Forfeited
Stock Options, Outstanding Ending Balance	123,500
Options, Vested	123,500
Weighted average exercise price, Outstanding Beginning Balance	$0.37
Weighted average exercise price, Granted	$0.14
Weighted average exercise price, Exercised
Weighted average exercise price, Cancelled
Weighted average exercise price, Forfeited
Weighted average exercise price, Outstanding Ending Balance	$0.35
Weighted average exercise price, Vested	$0.35
Weighted average remaining contractual life (years), Outstanding	9 years 2 months 12 days
Weighted average remaining contractual life (years), Granted	10 years
Weighted average remaining contractual life (years), Vested	9 years 3 months 18 days
Aggregate intrinsic value, Outstanding
Aggregate intrinsic value, Vested

SHAREHOLDERS_EQUITY_Details_2

SHAREHOLDERS' EQUITY (Details 2) (Stock Unit1 [Member])	3 Months Ended
	Mar. 31, 2015
Stock Unit1 [Member]
Stock Units, Outstanding Beginning Balance	8,270,239
Stock Units, Granted	10,507,143
Stock Units, Expired
Stock Units, Cancelled
Stock Units, Forfeited
Stock Units, Outstanding Ending Balance	18,777,382
Stock Units, Vested	11,403,623

SHAREHOLDERS_EQUITY_Details_3

SHAREHOLDERS' EQUITY (Details 3)	3 Months Ended
	Mar. 31, 2015
Expected life (in years)	6 years
Expected volatility	100.00%
Average risk free interest rate	1.54%
Dividend yield	0.00%
Warrant [Member]
Expected life (in years)	6 years
Expected volatility	100.00%
Average risk free interest rate	1.54%
Dividend yield	0.00%

SHAREHOLDERS_EQUITY_Details_4

SHAREHOLDERS' EQUITY (Details 4) (Warrant [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Warrant [Member]
Beginning balance, fair value of derivative liability
Value, January Debentures	15,000,000
Value, February Debentures	7,629,900
Change in fair value	1,122,300
Ending balance	$23,752,200

SHAREHOLDERS_EQUITY_Details_Te

SHAREHOLDERS' EQUITY (Details Textual) (USD $)	3 Months Ended			0 Months Ended	12 Months Ended	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Sep. 30, 2014	Feb. 15, 2013	Dec. 31, 2014	Sep. 30, 2013	Apr. 09, 2014	Sep. 18, 2013	Jan. 17, 2013
Common Stock, Shares Authorized	150,000,000
Common stock, par value	$0.00
Stock Issued During Period, Shares, Issued for Services	85,000
Stock Issuance Expenses	$44,000
Share-based Compensation Expense	630,518	654,226
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$138,928
Share-based Compensation, Total	19,450
Stock To Be Issued During Period For Services Value	285,142
Aggregate intrinsic value, Outstanding	0
Debt Exchange 1 [Member]
Debt exchanged	742,300
Share conversion price	$0.40
Shares of common stock issued in exchange of debt	1,855,747
Debt Exchange 2 [Member]
Shares of common stock issued in exchange of debt	1,900,000
Dawson James [Member]
Investment Warrants, Exercise Price	$0.10
Investment Warrants Expiration Date	6-Dec-18
Class of Warrant or Right, Outstanding	380,973
Compensation For Consulting Services	50,000
Compensation For Consulting Services Rate	8.00%
Principal And Accrued Interest Of Warrant	54,548
Jan 2014 Convertible Debenture [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	250,000
Investment Warrants, Exercise Price	$0.50
Investment Warrants Expiration Date	13-Feb-19
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	10,500		75,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	123,500				113,000
Employee stock option term	9 years 2 months 12 days
Aggregate intrinsic value, Outstanding
Stock Unit 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				6,000,000
Share Based Compensation Arrangement by Share Based Payment Award Options Vested In Period	500,000			2,000,000
Share-based Compensation not yet vested				4,000,000
Stock Issued During Period, Shares, Issued for Services				852,273
Share-based Compensation Expense	210,000
Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				300,000
Share Based Compensation Arrangement by Share Based Payment Award Options Vested In Period	24,999			208,325
Share-based Compensation Expense	9,333
2013 Equity Plan [Member]
Common Stock, Shares Authorized	10,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	62,000
Stock Issued During Period, Shares, Issued for Services	1,071,772
Available for future grant	459,489
Stock Issued During Period, Shares, New Issues	10,500				92,000
Share-based Compensation Expense	361,938
Employee stock option term	6 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$0.14				$0.31
Class of Warrant or Right, Outstanding	123,500
Units outstanding	8,345,239
2014 Equity Plan [Member]
Common Stock, Shares Authorized	20,000,000
Stock Issued During Period, Shares, Issued for Services	10,390,000
Available for future grant	9,630,000
Units outstanding	10,390,000
Consultant [Member]
Share-based Goods and Non-employee Services Transaction, Quantity of Securities Issued	200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	100,000
Stock Issued During Period, Shares, Issued for Services	126,296
Stock To Be Issued During Period For Services Value	55,521
Restricted stock issued	10,370,000
Restricted stock, vested, expense	483,933
Consultant 2 [Member]
Stock Issued During Period, Shares, Issued for Services	85,000
Stock To Be Issued During Period For Services Value	37,900
Dillen [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	200,000
Share-based Compensation not yet vested	400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	300,000
Stock Issued During Period, Shares, Issued for Services	600,000
Share-based Compensation Expense	75,932
Board of Directors Chairman [Member] | Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	500,000
Stock Issuance Expenses	37,000
Share-based Compensation Expense	1,184,250
Investor Relations Agreement [Member]
Common Stock, Shares Authorized							300,000	690,000	250,000
Share-based Goods and Non-employee Services Transaction, Quantity of Securities Issued	600,000	300,000
Stock Issuance Expenses	$187,500	$159,450	1,000			$26,000

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (BroadMed [Member], USD $)	1 Months Ended
	8-May-15
BroadMed [Member]
Eligible royalty payments	$11,100,000